Renovaro Biosciences (RENB) 10-K 10 Oct 24 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jun. 30, 2024	Oct. 03, 2024	Dec. 31, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	001-38758
Entity Registrant Name	RENOVARO INC.
Entity Central Index Key	0001527728
Entity Tax Identification Number	45-2559340
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2080 Century Park East
Entity Address, Address Line Two	Suite 906
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90067
City Area Code	305
Local Phone Number	918-1980
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	RENB
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 57,193,356
Entity Common Stock, Shares Outstanding		156,193,912
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	3627
Auditor Name	Sadler, Gibb & Associates, LLC
Auditor Location	Draper, UT

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2024	Jun. 30, 2023
CURRENT ASSETS:
Cash	$ 220,467	$ 1,874,480
Insurance receivable	1,108,247	0
Prepaids and other assets	668,929	690,925
Total Current Assets	1,997,643	2,565,405
Property and equipment, net	482,121	508,989
OTHER ASSETS
Definite life intangible assets, net	30,043	39,676
Indefinite life intangible assets, net	0	42,611,000
Goodwill	159,330,161	11,640,000
Deposits and other assets	19,849	21,741
Operating lease right-of-use assets	1,269,633	913,985
Total Other Assets	160,649,686	55,226,402
TOTAL ASSETS	163,129,450	58,300,796
CURRENT LIABILITIES:
Accounts payable – trade	9,448,683	5,296,823
Accrued expenses	5,311,324	723,173
Other current liabilities	295,361	184,733
Contingent consideration liability	12,310,000	0
Convertible notes payable	245,000	0
Current portion of operating lease liabilities	493,553	193,422
Notes payable – related parties, net	2,205,996	4,624,947
Total Current Liabilities	30,309,917	11,023,098
NON-CURRENT LIABILITIES:
Operating lease liabilities, net of current portion	842,389	775,587
Total Non-Current Liabilities	842,389	775,587
Total Liabilities	31,152,306	11,798,685
STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $0.0001, 350,000,000 shares authorized, 155,027,245 shares issued and outstanding at June 30, 2024; 63,698,144 shares issued and outstanding at June 30, 2023	15,504	6,371
Additional paid-in capital	456,811,911	290,554,875
Accumulated deficit	(324,679,425)	(244,029,253)
Accumulated other comprehensive (loss)	(170,846)	(29,882)
Total Stockholders’ Equity	131,977,144	46,502,111
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 163,129,450	$ 58,300,796

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2024	Jun. 30, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	155,027,245	63,698,144
Common stock, shares outstanding	155,027,245	63,698,144

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating Expenses
General and administrative	$ 24,557,608	$ 15,318,198
Research and development	2,708,829	4,165,197
Intangible asset impairment	42,611,000	18,960,000
Goodwill impairment	11,640,000	0
Depreciation and amortization	121,859	113,496
Total Operating Expenses	81,639,296	38,556,891
LOSS FROM OPERATIONS	(81,639,296)	(38,556,891)
Other Income (Expense)
Change in fair value of contingent consideration	4,727,473	0
Loss on extinguishment of debt	(1,303,578)	0
Loss on extinguishment of contingent consideration liability	0	(419,182)
Interest expense	(1,011,322)	(580,344)
Gain (loss) on foreign currency transactions	0	(1,019)
Interest income and other income (expense)	(1,423,449)	(126,620)
Total Other Income (Expense)	989,124	(1,127,165)
NET LOSS	$ (80,650,172)	$ (39,684,056)
BASIC NET LOSS PER COMMON SHARE	$ (0.84)	$ (0.71)
DILUTED NET LOSS PER COMMON SHARE	$ (0.84)	$ (0.71)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - BASIC	96,248,090	56,265,362
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING - DILUTED	96,248,090	56,265,362

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net Loss	$ (80,650,172)	$ (39,684,056)
Other Comprehensive Income (Loss)
Foreign currency translation, net of taxes	(140,964)	554
Comprehensive Loss	$ (80,791,136)	$ (39,683,502)

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Jun. 30, 2022		$ 5,302	$ 276,989,179	$ (204,345,197)	$ (30,436)	$ 72,618,848
Beginning balance, shares at Jun. 30, 2022		53,007,082
Stock issued pursuant to warrants exercised		$ 125	1,624,875			1,625,000
Stock issued pursuant to warrants exercised, shares		1,250,000
Earn-out shares issued		$ 125	2,762,375			2,762,500
Earn-out shares issued, shares		1,250,000
Shares issued for interest on $1.2 million notes payable extension		$ 20	204,372			204,392
Shares issued for interest on $1.2 million notes payable extension, shares		198,439
Issuance of common stock and warrants under private placement offering		$ 483	4,011,339			4,011,822
Issuance of common stock and warrants under private placement offering, shares		4,832,452
Restricted shares issued for services rendered		$ 20	227,980			228,000
Restricted shares issued for services rendered, shares		200,000
Conversion of convertible promissory notes		$ 226	1,199,774			1,200,000
Conversion of convertible promissory notes, shares		2,264,150
Issuance of restricted commitment shares		$ 70	(70)
Issuance of restricted commitment shares, shares		696,021
Stock-based compensation			3,535,051			3,535,051
Net loss				(39,684,056)		(39,684,056)
Foreign currency translation adjustment					554	554
Ending balance, value at Jun. 30, 2023		$ 6,371	290,554,875	(244,029,253)	(29,882)	46,502,111
Ending balance, shares at Jun. 30, 2023		63,698,144
Issuance of preferred stock and warrants in private placement	$ 28		1,999,972			2,000,000
Issuance of preferred stock and warrants for conversion of Note Payable	28		1,999,973			2,000,001
Restricted shares issued for services rendered		$ 308	4,663,882			4,664,190
Restricted shares issued for services rendered, shares		3,083,760
Exercise of warrants		$ 396	2,341,470			2,341,866
Exercise of warrants, shares		3,951,344
Issuance of common stock and warrants under private placement offering in settlement of debt		$ 566	10,575,759			10,576,106
Issuance of common stock and warrants under private placement offering in settlement of debt, shares		5,660,042
Shares issuable for settlement of contingent consideration		$ 219	3,519,808			3,520,027
Shares issuable for settlement of contingent consideration, shares		2,189,672
Issuance of common stock pursuant to acquisition of GEDi Cube		$ 7,083	135,994,548			136,001,631
Issuance of common stock pursuant to acquisition of GEDi Cube, shares		70,834,183
Preferred stock converted to common stock pursuant to acquisition of GEDi Cube	$ (56)	$ 561	(505)
Preferred stock converted to common stock pursuant to acquisition of GEDi Cube, shares	(561,010)	5,610,100
Issuance of options for services rendered			489,000			489,000
Stock-based compensation			4,673,129			4,673,129
Net loss				(80,650,172)		(80,650,172)
Foreign currency translation adjustment					(140,964)	(140,964)
Issuance of preferred stock and warrants in private placement, shares	280,505
Issuance of preferred stock and warrants for conversion of Note Payable, shares	280,505
Ending balance, value at Jun. 30, 2024		$ 15,504	$ 456,811,911	$ (324,679,425)	$ (170,846)	$ 131,977,144
Ending balance, shares at Jun. 30, 2024		155,027,245

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (80,650,172)	$ (39,684,056)
ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
Depreciation and amortization	121,859	113,496
Change in fair value of contingent consideration	(4,727,473)	0
Loss on extinguishment of contingent consideration liability	0	419,182
Loss on extinguishment of debt	1,303,578
Non-cash stock-based compensation expense	4,673,129	3,535,051
Non-cash restricted shares issued for services rendered	4,664,190	228,000
Intangible asset impairment	42,611,000	18,960,000
Goodwill impairment	11,640,000	0
Amortization of discount on note payable	580,605	348,621
Changes in assets and liabilities:
Insurance receivable	(1,108,247)	46
Prepaid expenses/deposits	1,082,267	1,070,249
Accounts payable	4,057,282	3,894,955
Other current liabilities	0	(54,060)
Operating leases, net	11,284	(27,224)
Accrued expenses	4,769,268	(578,809)
NET CASH USED IN OPERATING ACTIVITIES	(10,971,430)	(11,774,549)
CASH FLOWS FROM INVESTING ACTIVITIES:
Notes receivable prior to acquisition	(1,255,600)	0
Cash received from acquisition, net	65,851	0
Purchase of property and equipment	(70,430)	(29,774)
NET CASH USED IN INVESTING ACTIVITIES	(1,260,179)	(29,774)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments of finance agreement	(870,073)	(1,121,767)
Proceeds from exercise of warrants	341,865	1,625,000
Proceeds from private placements	3,000,000	4,011,823
Proceeds from issuance of promissory notes	3,770,512	0
Proceeds from convertible notes payable	4,275,151	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	10,517,455	4,515,056
Effect of exchange rates on cash	60,141	(8,395)
NET INCREASE (DECREASE) IN CASH	(1,654,013)	(7,297,662)
CASH, BEGINNING OF PERIOD	1,874,480	9,172,142
CASH, END OF PERIOD	220,467	1,874,480
Cash Paid during the year for:
Interest	20,128	352,334
Income Taxes	0	0
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Contingent Shares issued pursuant to Acquisition Agreement	0	2,762,500
Shares in lieu of interest on $1.2 million notes payable extension	0	204,392
Finance agreement entered into in exchange for prepaid assets	906,834	1,139,875
Conversion of note payable for issuance of preferred stock	2,000,001	0
Note payable settled through non-cash exercise of warrants	2,000,000	0
Debt discount related to notes payable	339,342	0
Common shares issued upon acquisition	136,001,631	0
Contingent consideration issued upon acquisition	20,557,500	0
Common shares issued upon settlement of debt	9,582,912	0
Earn out shares issued in settlement of contingent liability	3,520,027	0
Options issued in settlement of debt	489,000	0
Settlement of notes payable	$ 418,503	$ 0

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (80,650,172)	$ (39,684,056)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Business – Basis of Presentation Principles of Consolidation Subsidiaries Renovaro Biosciences Denmark ApS (“Renovaro Denmark”), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and it became a 100% owned subsidiary of Renovaro subject to 185,053 shares of Common Stock of Renovaro held in escrow according to Danish law (the “Escrow Shares”). As of June 30, 2024, there are 17,414 On February 13, 2024, the Company acquired 100 Use of Accounting Estimates Functional Currency and Foreign Currency Translation Cash and Cash Equivalents Concentration of Credit Risk Insurance Receivable Property and Equipment Intangible Assets Definite life intangible assets relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, Goodwill and Other Intangible Assets Indefinite life intangible assets include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than the carrying amount. Goodwill Impairment of Goodwill and Indefinite Lived Intangible Assets For indefinite life intangible assets, such as IPR&D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2023, the carrying value of the IPR&D exceeded its fair value. Therefore, the Company recorded an impairment loss of $18,960,000 during the year ended June 30, 2023. During the year ended June 30, 2024, the Company recorded an impairment loss of $42,611,000 related to the termination of the license agreement with Weird Science LLC (see Note 5.) The carrying value of IPR&D and goodwill at June 30, 2024, were zero 0 159,330,161 Impairment of Long-Lived Assets Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. No Leases Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the consolidated statements of operations. Research and Development Expenses 2,708,829 4,165,197 Income Taxes Loss Per Share 152,837,573 63,698,144 17,146,315 7,949,513 Fair Value of Financial Instruments Level 3 liabilities held as of June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2024, acquisition of Renovaro Cube Stock-Based Compensation FASB ASC Topic 718, Compensation – Stock Compensation 4,673,129 3,535,051 . The Company recognizes compensation costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur. The Company records stock-based compensation for services received from non-employees in accordance with ASC 718, Compensation—Stock Compensation Non-Employees The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Accordingly, the Company has elected to use the “simplified method” to estimate the expected term of its share-based awards. The simplified method computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two. New Accounting Pronouncements Not Yet Adopted

GOING CONCERN

GOING CONCERN	12 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 2 – GOING CONCERN The Company’s consolidated financial statements are prepared using the generally accepted accounting principles applicable to a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has incurred substantial recurring losses from continuing operations, has used cash in the Company’s continuing operations, and is dependent on additional financing to fund operations. The Company incurred a net loss of $ 80,650,172 39,684,056 220,467 324,679,425 28,312,274 Management has reduced overhead and administrative costs by streamlining the organization to focus around the development and validation of its AI driven cancer diagnostics platform. The Company has tailored its workforce to focus on these activities. In addition, the Company intends to attempt to secure additional required funding through equity or debt financing. However, there can be no assurance that the Company will be able to obtain any sources of funding. Such additional funding may not be available or may not be available on reasonable terms, and, in the case of equity financing transactions, could result in significant additional dilution to our stockholders. If we do not obtain required additional equity or debt funding, our cash resources will be depleted and we could be required to materially reduce or suspend operations, which would likely have a material adverse effect on our business, stock price and our relationships with third parties with whom we have business relationships, at least until additional funding is obtained. If we do not have sufficient funds to continue operations, we could be required to seek bankruptcy protection or other alternatives that could result in our stockholders losing some or all of their investment in us. Funding that we may receive during the fiscal year 2025 is expected to be used to satisfy existing and future obligations and liabilities and working capital needs, to support commercialization of our products, to conduct the clinical and regulatory work to develop our product candidates, and to begin building working capital reserves.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 3 — FAIR VALUE MEASUREMENTS The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820, “Fair Value Measurements”. The authoritative guidance among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: ● Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities; ● Level 2. Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and ● Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. There were no Level 1, 2 or 3 assets, nor any Level 1 or 2 liabilities as of June 30, 2024. Level 3 liabilities held as of June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2014, acquisition of Renovaro Cube, (the “Acquisition”). As consideration for the Acquisition, the stockholders of Renovaro Cube received (i) 70,834,183 20,557,500 7,613,301 The fair value of the contingent consideration liability is estimated using a Black-Scholes option-pricing model and a Monte-Carlo option pricing model. The key inputs to the model are all contractual or observable with the exception being volatility, which is computed based on the volatility of the Company’s underlying stock. The key inputs to valuing the contingent consideration liability as of June 30, 2024, were: Schedule of key input to valuing the contingent consideration liability Stock Price $ 1.75 Exercise Price $ 0.46 8.23 Volatility 109 145 Risk Free Rate 4.24 5.21 Expected Dividends 0 % Discount Rate (Monte-Carlo model only) 0 % Expected Term (years) 0.47 9.50 At initial recognition of the contingent consideration, the inputs were: Stock Price $ 1.92 Exercise Price $ 0.46 4.50 Volatility 107 133 Risk Free Rate 4.22 5.14 Expected Dividends 0 % Discount Rate (Monte-Carlo model only) 12 % Expected Term (years) 0.56 9.88 Unless otherwise disclosed, the fair value of the Company’s financial instruments including cash, accounts receivable, prepaid expenses, accounts payable, accrued expenses, lease obligations and notes payable approximate their recorded values due to their short-term maturities. The following table sets forth the Level 3 liability at June 30, 2024, which is recorded on the consolidated balance sheet at fair value on a recurring basis. As required, this liability is classified based on the lowest level of input that is significant to the fair value measurement: Schedule of fair value measurement on recurring basis Fair Value Measurements at Quoted Prices in Significant Other Significant Other Unobservable Inputs (Level 1) (Level 2) (Level 3) The roll forward of the contingent consideration liability is as follows: Balance June 30, 2023 — — $ — Contingent consideration in Acquisition — — 20,557,500 Settlements: contingent shares to be issued — — (3,520,027 ) Fair value adjustment — — (4,727,473 ) Contingent Consideration Liability at June 30, 2024 — — $ 12,310,000

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 - PROPERTY AND EQUIPMENT Property and equipment consisted of the following at June 30, 2024 and 2023: Schedule of property and equipment Useful Life June 30, 2024 June 30, 2023 Lab equipment and instruments 4 7 $ 639,998 $ 576,298 Leasehold improvements 10 224,629 224,629 Furniture, fixtures, and equipment 4 7 195,834 172,861 Total 1,060,461 973,788 Less accumulated depreciation (578,340 ) (464,799 ) Net Property and Equipment $ 482,121 $ 508,989 Depreciation expense amounted to $ 113,563 107,321

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND GOODWILL	NOTE 5 — INTANGIBLE ASSETS AND GOODWILL At June 30, 2024 and 2023, definite-life intangible assets, net of accumulated amortization, consisted of patents on the Company’s products and processes of $ 30,043 39,676 8,296 6,175 At June 30, 2024 and 2023, indefinite life intangible assets consisted of a license agreement classified as In-Process Research and Development (“IPR&D”) intangible assets, which are not amortizable until the intangible assets provide economic benefit, and goodwill. At June 30, 2024 and 2023, definite-life and indefinite-life intangible assets consisted of the following: Schedule of definite-life and indefinite-life intangible assets Useful Life June 30, 2023 Additions Amortization Impairment Translation Adjustment June 30, 2024 Definite Life Intangible Assets Patents 20 $ 290,936 $ — $ — $ — $ (5,959 ) $ 284,977 Less Accumulated Amortization (251,260 ) — (8,296 ) — 4,622 (254,934 ) Net Definite-Life Intangible Assets $ 39,676 $ — $ (8,296 ) $ — $ (1,337 ) $ 30,043 Indefinite Life Intangible Assets and Goodwill Goodwill 11,640,000 159,464,039 — (11,640,000 ) (133,878 ) 159,330,161 IPR&D 42,611,000 — — (42,611,000 ) — — Total Indefinite Life Intangible Assets and Goodwill $ 54,251,000 $ 159,464,039 $ — $ (54,251,000 ) $ (133,878) $ 159,330,161 Useful Life June 30, 2022 Period Change Effect of Currency Translation June 30, 2023 Definite Life Intangible Assets Patents 20 $ 279,257 $ — 11,679 $ 290,936 Less Accumulated Amortization (234,989 ) (6,175 ) (10,096 ) (251,260 ) Net Definite-Life Intangible Assets $ 44,268 $ (6,175 ) $ 1,583 $ 39,676 Indefinite Life Intangible Assets License Agreement $ 61,571,000 $ (18,960,000 ) $ — $ 42,611,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 73,211,000 $ (18,960,000 ) $ — $ 54,251,000 Expected future amortization expense is as follows: Schedule of expected future amortization expense Years ended June 30, 2025 $ 7,511 2026 7,511 2027 7,511 2028 7,510 Total $ 30,043 During February 2018, the Company acquired IPR&D related to a License Agreement (as licensee) to an HIV therapy which consists of a perpetual, fully paid-up, royalty-free, sub-licensable, and sole and exclusive worldwide license to research, develop, use, sell, have sold, make, have made, offer for sale, import and otherwise commercialize certain intellectual property in cellular therapies for the prevention, treatment, amelioration of and/or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans. The IPR&D intangible asset was classified as an indefinite life asset that was tested annually for impairment. On February 13, 2024, the Company acquired Renovaro Cube as a wholly owned subsidiary pursuant to a stock purchase agreement. As part of the acquisition of Renovaro Cube, the Company acquired goodwill valued at $159,464,039. Impairment – On March 1, 2024, the Company received a notice from the sole manager of Weird Science LLC terminating the License Agreement by and between Weird Science LLC and Enochian Biopharma, Inc. (now known as Renovaro Biosciences, Inc.), a wholly owned subsidiary of the Company, dated February 16, 2018. Due to the termination of the License Agreement, the Company recorded an impairment of $42,611,000 during the year ended June 30, 2024. Following the fourth quarter of each year, management performs its annual test of impairment of intangible assets by performing a assessment and determines if it is more likely than not that the fair value of the asset is greater than or equal to the carrying value of the asset. During the year ended June 30, 2023, the results of the assessment indicated that the carrying value of the licenses acquired as an IPR&D asset exceeded its fair value, due to the changes in the projected economic benefits to be realized from these assets. Therefore, an impairment adjustment of $ 18,960,000 During the year ended June 30, 2024, the results of the assessment indicated that the carrying value of the goodwill related to the RENB reporting unit exceeded its fair value, due to the changes in the projected economic benefits to be realized from this reporting unit. Management concluded the significant driver for the change in the economic benefits was due to the Company’s continued inability to raise capital for the further development of the technologies within this reporting unit. Therefore, an impairment adjustment of $ 11,640,000

LEASES

LEASES	12 Months Ended
	Jun. 30, 2024
Leases
LEASES	NOTE 6 — LEASES Operating Leases On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold improvements that was not utilized. On June 19, 2018, Renovaro entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050. Sublease Agreement Renovaro Cube leases an office facility in Amsterdam, Netherlands, under a 30-month operating lease agreement commencing on September 1, 2023, with a maturity date of February 28, 2026. In determining lease asset values, the Company considers fixed and variable payment terms, prepayments, incentives, and options to extend, terminate or purchase. The Company identified and assessed the following significant assumptions in recognizing the right-of-use assets and corresponding liabilities: Expected lease term 2.54 Incremental borrowing rate 5.14 Lease and non-lease components Below are the lease commitments for the next 5 years: Schedule of lease commitments Years Ending June 30 Lease Expense 2025 $ 554,453 2026 457,876 2027 334,788 Thereafter 79,830 Less imputed interest (91,005 ) Total $ 1,335,942 Sublease Agreement On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022. In accordance with ASC Topic 842, the Company treated the sublease as a separate lease, as the Company was not relieved of the primary obligation under the original lease. The Company continues to account for the Century City Medical Plaza lease as a lessee and in the same manner as prior to the commencement date of the sublease. The Company accounted for the sublease as a lessor of the lease. The sublease was classified as an operating lease, as it did not meet the criteria of a sales-type or direct financing lease. On April 18, 2023, the Company entered into a sublease termination agreement with the Subtenant, whereby the Subtenant and the Company agreed to terminate the sublease effective as of April 30, 2023. The Subtenant agreed to pay the Company $ 139,460 35,540 175,000 The Company recognized operating income from the sublease on a straight-line basis in its statements of operations over the sublease term. During the year ended June 30, 2024 and 2023, the net operating lease expenses were as follows: Schedule of net operating lease expenses Years ended June 30, 2024 2023 Operating Lease Expense $ 383,549 $ 322,447 Sub-lease Income — (352,700 ) Total Net Lease Expense $ 383,549 $ (30,253 ) Lease expense charged to general and administrative expenses for the years ended June 30, 2024 and 2023, amounted to $ 383,549 322,447 380,983 439,519 322,447 439,519 77,242

DEBT

DEBT	12 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
DEBT	NOTE 7 — DEBT Convertible Notes Payable — March 2024 Note — 500,000 10 March 15, 2025 On June 14, 2024, the Company sold 344,966 0.0001 512,361 1.4726 In the year ended June 30, 2024, the Company recorded interest expense of $ 12,361 0 The 2024 Notes — 460,000 12 January 11, 2025 3.38 125,000 125,000 12 December 29, 2024 3.38 On June 14, 2024, the Company sold 325,508 0.0001 483,460 1.4726 125,000 December 2023 Notes — 560,000 560,000 440,000 100,000 20,000 12 3.38 On June 14, 2024, in a private placement the Company sold 317,715 440,000 28,453 66,000 0.0001 1.4726 120,000 In the year ended June 30, 2024, the Company has recorded interest expense of $ 67,013 245,000 120,000 125,000 The 2023 Notes — 5 2,105,263 2,000,000 5 105,263 12 September 5, 2024 The 2023 Notes were subject to mandatory conversion (“Mandatory Conversion”) in the event the Company closed an offering of its Common Stock and received gross proceeds of not less than $ 10,000,000 95 4.50 4.50 On January 11, 2024, the Company entered into an amendment with one of the investors of the 2023 Notes whereas the conversion terms were amended to provide for optional conversion at a conversion price of $ 3.38 On June 14, 2024, the Company sold 1,546,449 2,293,825 443,575 318,063 0.0001 1.4726 1.4765 0 For the year ended June 30, 2024, discount amortization of $ 78,567 26,696 189,614 0 The Convertible Notes — 600,000 6 The conversion price was equal to $12.00 per share of Common Stock. The Holder did not exercise its conversion feature that expired on February 6, 2021. The Company evaluated the Convertible Notes in accordance with ASC 470-20 and identified that they each contain an embedded conversion feature that shall not be bifurcated from the host document (i.e., the Convertible Notes) as they are not deemed to be readily convertible into cash. Effective December 30, 2022 (the “Effective Date”), the Company amended and restated the Convertible Notes (the “Amended and Restated Secured Notes”). Pursuant to the Amended and Restated Secured Notes, the due date was extended to February 28, 2024 12 198,439 29,419 169,020 1.03 1,200,000 204,392 174,090 30,302 the Holder notified the Company that it wished to elect to exercise its conversion right triggered by a private placement. Therefore, all outstanding $ 1,200,000 1,132,075 Notes Payable Bridge Loans — 2,098,252 10 1,424,862 1.4726 2,098,252 On February 5, 2024, the Company entered into an agreement with RS Bio ApS, a Danish entity controlled by the Company’s Chairman, Rene Sindlev (“RS Bio”) to issue a 5 105,263 100,000 5 12 March 1, 2024 5,263 6,316 105,263 On January 2, 2024, the Company entered into an agreement with RS Bio to issue a 5 526,315 500,000 5 12 March 1, 2024 26,315 31,579 526,315 On November 22, 2023, Renovaro Cube entered into a loan agreement where the holder agreed to loan the Company up to £500,000 (approximately $624,000 USD). The note had a repayment date occurring the first business day after the first anniversary of the draw down of the loan. The first draw down of £250,000 occurred on November 27, 2023, and the second draw down of £250,000 occurred on December 13, 2023. The Company paid interest on the loan at the rate of 10 454,708 665,387 100,400 36,388 0 On November 3, 2023, the Company entered into an agreement with RS Bio to issue a 5 1,000,000 950,000 5 50,000 12 January 1, 2024 March 1, 2024 471,699 0.53 250,000 50,000 69,083 750,000 Promissory Note — 5,000,000 November 30, 2021 6 188,485 501,370 493,192 493,192 On February 11, 2021, the Company entered into an amendment to the Promissory Note that extended the Maturity Date to November 30, 2022. All other terms of the Promissory Note remained the same. The change in Maturity Date required an additional year of interest at the fixed rate of 6 74,054 298,178 On May 17, 2022, the Company entered into a second amendment to the Promissory Note that extended the Maturity Date to November 30, 2023 6 12 47,115 299,178 Effective December 30, 2022, the Company entered into a third amendment to the Promissory Note. Pursuant to the third amendment, the Company’s obligations under the Promissory Note were secured by a Security Agreement. To secure the Company’s obligations under each of the Amended and Restated Secured Notes and the Promissory Note, the Company entered into a Security Agreement with the Holder, pursuant to which the Company granted a lien on all assets of the Company (the “Collateral”) for the benefit of the Holder. Upon an Event of Default (as defined in the Amended and Restated Secured Notes and Promissory Note, respectively) the Holder may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease, or dispose of the Collateral. On June 12, 2023, the Holder notified the Company that it wanted to apply the Interest Payment due to it towards the Company’s next private placement. Therefore, on June 26, 2023, in conjunction with the Company’s private placement, the Company issued (i) 567,588 0.0001 283,794 0.53 300,822 On July 31, 2023, the Company and the Holder agreed to amend the Promissory Note (the “Fourth Amendment”) to provide the Holder with limited conversion rights in connection with the Company’s next private placement. Per the terms of the Fourth Amendment, the Holder could elect to convert $2 million of the outstanding principal balance of the Promissory Note into the Units being offered in a private placement at the price per Unit being paid by the investors in the private placement (the “Conversion Right”). On August 1, 2023, the Holder notified the Company of its election to exercise the Conversion Right. As a result, $2 million of the outstanding principal balance of the Promissory Note was converted into 280,505 Units at $7.13 per unit, comprised of an aggregate of (i) 280,505 shares of Series A Convertible Preferred Stock of the Company and (ii) Warrants to purchase an aggregate of 1,402,525 shares of Common Stock with an exercise price of $0.65 per share. The Series A Convertible Preferred Stock acquired by the Holder was initially convertible into 2,805,050 shares of Common Stock. A $3 million principal balance remained outstanding under the Promissory Note after the foregoing conversion. The Company concluded that in accordance with ASC 470-20-40-4, the difference between the fair value of the Preferred Shares and warrants and the carrying value of the portion of the Note being converted should be recognized as an extinguishment. The extinguishment loss of $120,018 is recorded in Other Income/Loss in the Statement of Operations. On November 30, 2023, the Company and the Holder agreed to amend the Promissory Note (the “Fifth Amendment”) such that the Company and the Holder extended the maturity of the original Promissory Note until February 29, 2024. In addition, all interest payable from November 30, 2023 to the Maturity Date was payable and is currently payable by the Company as of November 30, 2023. On February 16, 2024, the Company received notice from the Holder to exercise 2,953,700 warrants outstanding ranging from $0.53 to $0.65 per share and apply $1,750,000 of the note balance to the exercise price of the warrants. On February 29, 2024, the Company and the Holder agreed to amend the Promissory Note (the “Sixth Amendment”) to where the Company and the Holder extended the maturity of the original Promissory Note until May 1, 2024. On May 1, 2024, the Company and the Holder agreed to amend the Promissory Note (the “Seventh Amendment”) to extend the maturity of the original Promissory Note until August 1, 2024. On June 14, 2024 the Holder requested the Company repay $ 418,503 100,440 318,063 418,503 393,763 348,621 824,418 Finance Agreement On November 30, 2023, the Company entered into a premium finance agreement (the “Agreement”) related to insurance, which resulted in the recognition of a liability and prepaid expense with a principal amount of $ 906,834 7.90 77,127 235,000 870,073 1,121,767 231,381 For the years ended June 30, 2024 and 2023 the Company recorded total interest expense in the amount of $ 20,128 21,180 related to the Agreement. This amount is reflected in other income and expenses. Total interest expense recorded for the years ended June 30, 2024 and 2023, was $ 1,011,322 580,344

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 8 — INCOME TAXES The Company accounts for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit carryforwards. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which cannot be determined. As of June 30, 2024 and 2023, the Company had net operating loss carryforwards of approximately $ 489,177,759 476,965,239 144,191,530 140,547,314 The Company files Danish and U.S. income tax returns and these returns are generally no longer subject to tax examinations for years prior to 2020 for the Danish tax returns and 2021 for the U.S. tax returns. The temporary differences, tax credits and carry forwards gave rise to the following deferred tax assets (liabilities) at June 30, 2024 and 2023: June 30 2024 2023 Excess of tax over book depreciation of fixed assets $ 8,258 $ 8,258 Excess of tax over book depreciation of patents 8,415 8,415 Stock/options compensation 6,672,252 3,885,996 Depreciation and amortization 188,422 152,059 Net operating loss carryforwards 144,191,530 140,547,314 Impairment expense 16,188,497 — Contingent consideration fair value 1,410,678 — Change in tax rate — — Valuation allowance (168,668,052 ) (144,602,042 ) Total Deferred Tax Assets (Liabilities) $ — $ — In accordance with prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine whether the tax position meets the more-likely-than-not condition for recognition, and the second step is to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company’s future earnings, and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance was recorded for all deferred tax assets. A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company’s effective rate is as follows for the years ended June 30, 2024 and 2023: Schedule of reconciliation of income tax expense Years ended June 30, 2024 2023 Computed tax at expected statutory rate $ (24,066,011 ) $ (70,341,751 ) Non-US income taxed at different rates — — Non-deductible expenses / other items — — Valuation allowance 24,066,011 70,341,751 Income Tax Expense (Benefit) $ — $ — The components of income tax expense (benefit) from continuing operations for the years ended June 30, 2024 and 2023 consisted of the following: Years ended June 30, 2024 2023 Current Income Tax Expense Danish income tax (benefit) $ — $ — Total Current Tax Expense (Benefit) $ — $ — Deferred Income Tax Expense (Benefit) Excess of tax over book depreciation of fixed assets $ 8,258 $ 8,258 Excess of tax over book depreciation of patents 8,415 8,415 Stock/options compensation 6,672,252 3,885,996 Depreciation and amortization 188,422 152,059 Net operating loss carryforwards 144,191,530 140,547,314 Impairment expense 16,188,497 — Contingent consideration fair value 1,410,678 Change in tax rate — — Change in the valuation allowance (168,668,052 ) (144,602,042 ) Total Deferred Tax Expense $ — $ — Deferred income tax expense (benefit) results primarily from the reversal of temporary timing differences between tax and financial statement income.

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	12 Months Ended
	Jun. 30, 2024
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 9 — STOCKHOLDERS’ EQUITY Preferred Stock 10,000,000 0.0001 1,000,000 0 Voting — Dividends — Liquidation Rights — Conversion Rights — Common Stock 350,000,000 0.0001 155,027,245 63,698,144 2,189,672 Voting — Dividends — Liquidation Rights — Purchase Agreement with Lincoln Park Capital On June 20, 2023, the Company entered into a purchase agreement (the “2023 Purchase Agreement”) with Lincoln Park, pursuant to which the Company may sell and issue to Lincoln Park, and Lincoln Park is obligated to purchase, up to $ 20,000,000 In consideration for entering into the 2023 Purchase Agreement, the Company issued 696,021 During the years ended June 30, 2024 and June 30, 2023 no shares of Common Stock to Lincoln Park were sold under the Purchase Agreement. Preferred Stock Issuances On August 1, 2023, the Company closed a private placement of 280,505 Units Preferred Stock Warrant Securities 7.13 2,000,000 280,505 2,000,000 The Company issued an aggregate of 561,010 5,610,100 2,805,050 0.65 On February 13, 2024 pursuant to the acquisition of Renovaro Cube, the 561,010 5,610,100 120,018 June 2024 Private Placement On June 14, 2024, Renovaro Inc., a Delaware corporation (the “ Company 5,315,215 0.0001 1.4765 The Private Placement was completed pursuant to Regulation S promulgated under the Securities Act of 1933, as amended (“ Regulation S In the Private Placement, the Company sold 2,325,869 1.4726 3,425,075 Additionally, the Company sold 2,671,631 $ 3, 955,033 478,060 Additionally, the Company sold 317,715 468,453 66,000 In relation to the June 14, 2024 Private Placement the Company recognized a loss on the settlement of debt for $ 1,183,560 Common Stock Issuances On April 5, 2024, the Company issued 33,760 94,190 On February 20, 2024, 2,953,700 0.53 0.65 1,750,000 On February 20, 2024, 471,699 0.53 250,000. On February 15, 2024, the Company issued 50,000 100,000 On February 15, 2024, the Company closed a private placement of 344,827 0.0001 1,000,000 On February 13, 2024, the Company issued 70,834,183 valued at $ 136,001,631 (see Note 12) shares of Common Stock pursuant to the Stock Purchase Agreement of Renovaro Cube. On December 4, 2023, the Company issued 525,945 341,865 On October 23, 2023, the Company issued 1,000,000 2,760,000 Between July 28, 2023, and September 28, 2023, the Company issued 2,000,000 4,470,000 On June 26, 2023, the Company issued 4,718,532 2,359,266 1,300,823 1,200,000 0.53 0.53 On June 26, 2023, the Company issued 4,718,532 2,359,266 1,300,823 1,200,000 0.53 0.53 On June 20, 2023, the Company issued 696,021 On April 27, 2023, there were 100,000 120,000 During March 2023, the Company issued 2,378,070 1,189,036 2,711,000 1.14 1.14 On February 10, 2023, there were 100,000 108,000 On December 30, 2022, the Company issued 198,439 204,392 On July 14, 2022, certain of our warrant holders exercised warrants to purchase 1,250,000 1,625,000 2.21 2,762,500 2.21 2017 Warrants On July 14, 2022, certain of our warrant holders exercised warrants to purchase 1,250,000 1,625,000 2,762,500 2.21 419,182 Acquisition of Renovaro Biopharma / Contingently issuable shares On February 16, 2018, the acquisition of Renovaro Biosciences was completed. As part of the acquisition, the stockholders of Renovaro Biosciences received (i) 18,081,962 shares of Common Stock, and (ii) the right to receive Contingent Shares of Common Stock pro rata upon the exercise or conversion of warrants, which were outstanding at closing. As of June 30, 2024, no Acquisition of Renovaro Denmark At June 30, 2024 and 2023, the Company maintained a reserve of 17,414 167,639 no Stock-based Compensation The Company recognizes compensation costs for stock option awards to employees based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. In the year ended June 30, 2024, the weighted-average assumptions used to estimate the grant date fair values of the stock options granted using the Black-Scholes option-pricing model are as follows: Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted Renovaro Inc. Expected term (in years) 5.0 6.5 Volatility 84.33 114.88 % Risk free interest rate 3.12 4.83 % Dividend yield 0 % The Company recognized stock-based compensation expense related to all equity instruments of $ 4,673,129 3,535,051 250,373 Plan Options On February 6, 2014, the Company’s Board of Directors adopted the Company’s 2014 Equity Incentive Plan (the “2014 Plan”), and the Company had reserved 1,206,000 On October 30, 2019, the Board approved and on October 31, 2019, the Company’s stockholders adopted its 2019 Equity Incentive Plan (the “2019 Plan”), which replaced the 2014 Plan. The 2019 Plan provided that the maximum aggregate number of shares of the Company’s Common Stock reserved and available for issuance under the 2019 Plan was the sum of (1) 6,000,000 new shares, and (2) the number of shares available for the grant of awards as of the effective date under the 2014 Plan plus any options related to awards that expire, are terminated, surrendered, or forfeited for any reason without issuance of shares under the 2014 Plan after the effective date of the 2019 Plan. Effective July 21, 2023, the Company adopted the Renovaro Biosciences Inc. 2023 Equity Incentive Plan (the “2023 Plan”). The 2023 Plan replaced the 2019 Plan. The 2023 Plan provides that the maximum aggregate number of shares of the Company’s Common Stock reserved and available for issuance under the 2023 Plan was the sum of (1) 4,000,000 new shares, and (2) the number of shares available for the grant of awards as of the effective date under the 2019 Plan. Any awards outstanding under the 2019 Plan as of the date of adoption of the 2023 Plan remain subject to and will be available under the 2019 Plan, and any shares subject to outstanding awards under the 2019 Plan that subsequently expire, terminate, or are surrendered or forfeited for any reason without issuance of shares automatically become available for issuance under the 2023 Plan. The Company granted options to purchase 369,500 193,000 During the year ended June 30, 2024 and 2023, the Company granted options to purchase zero 0 184,800 0 18,960 During the year ended June 30, 2024 and 2023, the Company granted options to purchase zero 0 73,200 0 12,640 65,000 During the years ended June 30, 2024 and 2023, the Company granted options to purchase 424,412 355,359 During the years ended June 30, 2024 and 2023, the Company granted options to purchase 329,729 0 During the years ended June 30, 2024, and 2023, the Company granted options to purchase 10,000 75,000 All of the above options are exercisable at the market price of the Company’s Common Stock on the date of the grant. On February 13, 2024, the Company repriced 3,849,931 eligible employee and consultant options from the original issued exercise price to a new exercise price of $1.92 per share, the closing price of the Company’s Common Stock on February 13, 2024. The Company recognized stock-based compensation expense related to the repricing of options of $921,254 during the year ended June 30, 2024. To date the Company has granted options under the 2014, 2019 and 2023 Plans (“Plan Options”) to purchase 6,665,821 4,515,873 A summary of the Plan Options outstanding at June 30, 2024 is presented below: Schedule of stock options outstanding Options Outstanding Options Exercisable Exercise Price Ranges Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 0.45 4.50 5,244,987 7.38 $ 1.89 3,817,105 7.15 $ 1.92 $ 4.51 6.50 167,634 6.48 $ 5.33 135,376 5.81 $ 5.49 $ 6.51 12.00 115,231 4.66 $ 7.63 111,585 4.57 $ 7.61 Total 5,527,852 7.29 $ 2.11 4,064,066 7.03 $ 2.20 A summary of changes are presented below: Schedule of stock option activity Shares Weighted Average Exercise Average Remaining Life Weighted Average Intrinsic Outstanding at June 30, 2023 4,401,211 $ 4.78 7.82 $ — Granted 4,983,572 $ 1.94 Exercised — $ — Forfeited — $ — Expired/Canceled (3,856,931 ) $ 4.94 Outstanding at June 30, 2024 5,527,852 $ 2.11 7.30 $ — Exercisable at June 30, 2024 4,064,066 $ 2.20 7.05 $ 525,943 At June 30, 2024, the Company had Plan Options to purchase 4,064,066 shares of common stock that were exercisable. The total intrinsic value of options exercisable at June 30, 2024, was $ 525,943 Common Stock Purchase Warrants A summary of the status of the Common Stock Purchase Warrants outstanding at June 30, 2024, is presented below: Schedule of common stock purchase warrants outstanding Warrants Outstanding Warrants Exercisable Exercise Price Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 0.53 471,698 1.33 471,698 1.33 $ 0.65 741,274 3.07 741,274 3.07 $ 1.14 1,189,036 3.73 1,189,036 3.73 $ 1.47 642,128 4.96 642,128 4.96 $ 1.48 50,740 4.99 50,740 4.99 Total 3,094,876 3.48 $ 1.00 3,094,876 3.48 $ 1.00 A summary of the warrant activity is presented below: Schedule of warrants outstanding Shares Weighted Average Exercise Weighted Average Remaining Outstanding at June 30, 2023 3,548,302 $ 0.73 4.80 Granted 3,497,918 $ 0.81 4.27 Exercised (3,951,344 ) $ 0.59 — Cancelled/Expired — $ — — Outstanding and exercisable at June 30, 2024 3,094,876 $ 1.00 3.48 At June 30, 2024, the Company had 3,094,876 2,309,681 Restricted Stock Awards (RSA) The Company recognized stock-based compensation expense related to RSAs of $ 1,415,157 1,000,000 2,760,000 1,344,843 The Company recognized stock-based compensation expense related to other RSAs of $ 108,000 100,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 — COMMITMENTS AND CONTINGENCIES Commitments On January 31, 2020, the Company entered into a Statement of Work and License Agreement (the “HBV License Agreement”) by and among the Company, G-Tech, and G Health Research Foundation, a not for profit entity organized under the laws of California doing business as Seraph Research Institute (“SRI”) (collectively the “Licensors”), whereby the Company acquired a perpetual, sublicensable, exclusive license (the “HBV License”) for a treatment under development (the “Treatment”) aimed to treat Hepatitis B Virus (HBV) infections. The HBV License Agreement states that in consideration for the HBV License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Treatment over a 24 month period, and provides for an up-front payment of $ 1.2 2 1.2 The cash funding for research costs pursuant to the HBV License Agreement consisted of monthly payments amounting to $144,500 that covered scientific staffing resources to complete the project as well as periodic payments for materials and equipment needed to complete the project. There were no payments made after January 31, 2022. The Company paid zero under the HBV License Agreement in the years ended June 30, 2024, and 2023. The Company has filed a claim against the Licensors, which includes certain payments it made related to this license (see Contingencies sub-section below). On April 18, 2021, the Company entered into a Statement of Work and License Agreement (the “License Development Agreement”), by and among the Company, G-Tech and SRI (collectively, the “Licensors”), whereby the Company acquired a perpetual sublicensable, exclusive license (the “Development License”) to research, develop, and commercialize certain formulations which were aimed at preventing and treating pan-coronavirus or the potential combination of the pan-coronavirus and pan-influenza, including the SARS-coronavirus that causes COVID-19 and pan-influenza (the “Prevention and Treatment”). The Development License Agreement was entered into pursuant to the existing Framework Agreement between the parties dated November 15, 2019. The Development License Agreement states that in consideration for the Development License, the Company shall provide cash funding for research costs and equipment and certain other in-kind funding related to the Prevention and Treatment over a 24-month period. Additionally, the License Agreement provides for an up-front payment of $ 10,000,000 760,000 The Development License Agreement provides for cooperation related to the development of intellectual property related to the Prevention and Treatment and for a 3% royalty to G-Tech on any net sales that may occur under the Development License Agreement. The Company is no longer pursuing any product candidates that relate to this license. The Company has filed a claim against the Licensors to recover all monies it paid related to this license (see Contingencies sub-section below). On August 25, 2021, the Company entered into an ALC Patent License and Research Funding Agreement in the HIV Field (the “ALC License Agreement”) with Serhat Gümrükcü and SRI (collectively, the “Licensors”) whereby the Licensors granted the Company an exclusive, worldwide, perpetual, fully paid-up, royalty-free license, with the right to sublicense, proprietary technology subject to a U.S. patent application, to make, use, offer to sell, sell or import products for use solely for the prevention, treatment, amelioration of or therapy exclusively for HIV in humans, and research and development exclusively relating to HIV in humans; provided the Licensors retained the right to conduct HIV research in the field. Pursuant to the ALC License Agreement, the Company granted a non-exclusive license back to the Licensors, under any patents or other intellectual property owned or controlled by the Company, to the extent arising from the ALC License, to make, use, offer to sell, sell or import products for use in the diagnosis, prevention, treatment, amelioration or therapy of any (i) HIV Comorbidities and (ii) any other diseases or conditions outside the HIV Field. The Company made an initial payment to SRI of $ 600,000 600,000 G-Tech and SRI are controlled by Anderson Wittekind, a stockholder of the Company. Shares held for non-consenting shareholders 17,414 Service Agreements – Contingencies Securities Class Action Litigation Federal Derivative Litigation State Derivative Litigation On October 21, 2022, the Company filed a Complaint in the Superior Court of the State of California for the County of Los Angeles against Serhat Gümrükcü, William Anderson Wittekind (“Wittekind”), G Tech Bio LLC (“G Tech”), SG & AW Holdings, LLC, and Seraph Research Institute (“SRI”) (collectively, the “Defendants”). The Complaint alleges that the Defendants engaged in a “concerted, deliberate scheme to alter, falsify, and misrepresent to the Company the results of multiple studies supporting its Hepatitis B and SARS-CoV-2/influenza pipelines.” Specifically, “Defendants manipulated negative results to reflect positive outcomes from various studies, and even fabricated studies out of whole cloth.” As a result of the Defendants’ conduct, the Company claims that it “paid approximately $25 million to Defendants and third-parties that it would not otherwise have paid.” On April 21, 2023, defendants Wittekind, G Tech, SG & AW Holdings, LLC, and SRI filed a demurrer with respect to some, but not all, of the Company’s claims, as well as a motion to strike. On September 6, 2023, the court denied in part and granted in part the pending motions. On September 7, 2023, the court entered a case management order setting the final status conference, trial, and other intervening deadlines. On December 4, 2023, the Defendants answered the Company’s First Amended Complaint and G Tech and SRI filed a Cross-Complaint. In the Cross-Complaint, G Tech and SRI seek declaratory and injunctive relief related to certain agreements between G Tech, SRI, and the Company, including, inter alia On March 1, 2021, the Company’s former Chief Financial Officer, Robert Wolfe and his company, Crossfield, Inc., filed a Complaint in the U.S. District Court for the District of Vermont against the Company, Renovaro Biosciences Denmark ApS, and certain directors and officers. In the Complaint, Mr. Wolfe and Crossfield, Inc. asserted claims for abuse of process and malicious prosecution, alleging, inter alia, that the Company lacked probable cause to file and prosecute an earlier action, and sought millions of dollars of compensatory damages, as well as punitive damages. The allegations in the Complaint relate to an earlier action filed by the Company and Renovaro Biosciences Denmark ApS in the Vermont Superior Court, Orange Civil Division. On March 3, 2022, the court partially granted the Company’s motion to dismiss, dismissing the abuse of process claim against all defendants and all claims against Mark Dybul and Henrik Grønfeldt-Sørensen. On November 29, 2022, the Company filed a motion for summary judgment with respect to the sole remaining claim of malicious prosecution. On August 24, 2023, the court denied the motion for summary judgment. The court vacated the July 15, 2024 trial date and has yet to re-set the trial date. The Company denies the allegations set forth in the Complaint and will continue to vigorously defend against the remaining claim. On June 7, 2023, Weird Science LLC (“Weird Science”), Wittekind, the William Anderson Wittekind 2020 Annuity Trust, the William Anderson Wittekind 2021 Annuity Trust, the Dybul 2020 Angel Annuity Trust, and the Ty Mabry 2021 Annuity Trust (such trusts, collectively, the “Trusts”) (collectively, “Plaintiffs”) filed a Verified Complaint against the Company in the Court of Chancery of Delaware. In the Verified Complaint, Plaintiffs alleged that the Company breached the February 16, 2018 Investor Rights Agreement between the Company, Weird Science, and RS Group ApS (the “Investor Rights Agreement”). According to the Verified Complaint, the Investor Rights Agreement required the Company to (i) notify all “Holders” of “Registrable Securities” at least 30 days prior to filing a registration statement and (ii) afford such Holders an opportunity to have their Registrable Securities included in such registration statement. Plaintiffs alleged that the Company breached these registration rights by failing to provide the required notice in connection with S-3 registration statements filed by the Company on July 13, 2020 and February 11, 2022. The Company moved to dismiss the Verified Complaint on September 15, 2023. On December 4, 2023, in lieu of opposing the motion to dismiss, Plaintiffs filed a Verified First Amended Complaint (“FAC”). In the FAC, Plaintiffs assert claims against the Company and others for purported breaches of the Investor Rights Agreement, fraud, tortious interference with a contract, and several other torts. Plaintiffs seek compensatory, exemplary, and punitive damages, as well as certain declaratory relief, specific performance, and pre- and post-judgment interest, costs, and attorneys’ fees. The Company filed a motion to dismiss the FAC on December 18, 2023. The Court scheduled oral argument on the motions to dismiss for November 15, 2024. The Company denies Plaintiffs’ allegations and intends to vigorously defend against the claims. On August 24, 2023, counsel on behalf of Weird Science, Wittekind, individually, and Wittekind, as trustee of the Trusts served a demand to inspect the Company’s books and records (the “Demand”) pursuant to Delaware General Corporation Law, § 220 (“Section 220”). The Demand seeks the Company’s books and records in connection with various issues identified in the Demand. The Company takes its obligations under Section 220 seriously and, to the extent that the requests are proper under Section 220, intends to comply with those obligations. On January 19, 2024, Weird Science and Wittekind sent the Company’s Board of Directors a letter demanding it take corrective actions with respect to twenty-one issues identified therein. On February 27, 2024, Weird Science and Wittekind sent the Company’s Board of Directors a supplemental letter that expanded their demand for corrective actions to twenty-six issues. In response to these demand letters, the Board of Directors initially formed a Special Committee (“Special Committee”) of independent directors on February 29, 2024. The Special Committee retained Stradling Yocca Carlson & Rauth LLP as its counsel to investigate the issues identified in the demand letters. The Special Committee’s investigation is ongoing. On January 23, 2024, Weird Science and Wittekind filed a shareholder derivative action in the United States District Court for the Central District of California against certain officers, directors, and investors of the Company, as well as other defendants, in connection with, inter alia On June 21, 2024, the Company filed suit against Weird Science, Wittekind, and certain trusts in connection with the February 16, 2018 merger involving the Company and two companies closely associated with Gumrukcu. In the complaint, the Company alleges that Gumrukcu and others deliberately and fraudulently concealed a murder-for-hire scheme from the Company in order to induce the Company to enter into the merger agreement, which resulted in the defendants receiving shares and compensation. The Company asserts claims for fraudulent concealment, equitable fraud, unjust enrichment, and civil conspiracy and seeks, inter alia

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jun. 30, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 11 — RELATED PARTY TRANSACTIONS As of June 30, 2024, the Company has accrued $ 220,402 On February 16, 2024, the Company received an exercise notice from RS Bio ApS (“RS Bio”) to exercise 471,699 0.53 250,000 On February 5, 2024, the Company entered into an agreement with RS Bio to issue a 5 105,263 100,000 5 12 March 1, 2024 5,263 6,316 105,263 On January 2, 2024, the Company entered into an agreement with RS Bio to issue a 5 526,315 500,000 5 12 March 1, 2024 26,315 31,579 526,315 On November 3, 2023, the Company entered into an agreement with RS Bio to issue a 5 1,000,000 950,000 5 50,000 12 January 1, 2024 On October 10, 2023, the Board of Directors of the Company (the “Board”) appointed Avram Miller to the Board, effective October 11, 2023, to fill a vacancy. Mr. Miller will serve until the Company’s 2024 Annual Meeting of Stockholders subject to this re-election or until his successor has been duly elected and qualified. In addition to Mr. Miller’s appointment to the Board, Mr. Miller, the co-founder of Intel Capital, entered into an advisory agreement with the Company (the “Advisory Agreement”), pursuant to which Mr. Miller will provide advice to the Board and the Company on various matters including strategic opportunities, capital allocation, business development, minority investments and licensing arrangements, among others. As compensation for these services, the Company will issue Mr. Miller 1,000,000 shares of restricted stock, 166,667 of which will vest in 2024, 444,444 will vest in 2025, and 388,889 will vest in 2026, subject to Mr. Miller’s continued service through each applicable vesting date. On August 1, 2023, RS Bio, purchased in a Private Placement 70,126 of the Company’s Units at a price per Unit equal to $7.13 for aggregate proceeds to the Company of $500,000. The Board of Directors (excluding Mr. Sindlev) approved the participation of certain officers and directors of the Company in the Private Placement on identical terms as the other investors of the Private Placement On August 1, 2023, Paseco ApS, in connection with the Private Placement, converted $2,000,000 of its Promissory Note into 280,505 of the Company’s Units at a price per Unit equal to $7.13. In addition, Paseco ApS purchased in the Private Placement 63,114 of the Company’s Units at a price per Unit equal to $7.13 for aggregate proceeds to the Company of $450,000. As a result of participation in the Private Placement, Paseco ApS was deemed to be an affiliate of the Company (see Note 7.) The Company currently has a consulting agreement with Paseco ApS for business advisory services since December of 2019. For the years ended June 30, 2023 and 2024 the Company issued zero and 1,000,000 restricted common shares, respectively, as payment for services rendered thereunder. The information set forth above in Note 7—Debt—Notes Payable—Promissory Note relating to the Promissory Note issued to Paseco ApS is incorporated herein by reference.

ACQUISITION

ACQUISITION	12 Months Ended
	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
ACQUISITION	NOTE 12 — ACQUISITION On September 28, 2023, the Company, entered into a Stock Purchase Agreement (the “ Purchase Agreement GEDi Cube Sellers Pursuant to the Stock Purchase Agreement, as of the Closing Date, the Company acquired all the issued and outstanding equity interests of GEDi Cube owned by the Sellers as of the Closing Date (each, a “GEDi Cube Share” and, collectively, the “GEDi Cube Shares”) in exchange for which each Seller was entitled to receive (i) as of the Closing Date, such Seller’s pro rata percentage of an aggregate of 70,834,183 shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”), which represents the 67,224,089 shares of Common Stock issued and outstanding as of the Closing Date (minus (a) 1 million shares of Common Stock previously issued to a consultant assisting with the Transaction and (b) 1 million shares of Common Stock previously issued to Avram Miller, a director of the Company, pursuant to his Advisory Agreement, dated October 11, 2023, by and between Mr. Miller and the Company) (the “Closing Consideration”) plus 5,610,100 shares of Common Stock representing the Seller’s Earnout Shares (defined below) resulting from the automatic conversion of the Company’s Series A Convertible Preferred and, (ii) following the Closing Date, such Seller’s pro rata percentage of the shares of Common Stock (the “Earnout Shares” and, together with the Closing Consideration, the “Exchange Consideration”) to be issued to the Sellers upon the exercise or conversion of any of the Company’s derivative securities (subject to certain exceptions) that are outstanding at the Closing Date (the “Closing Derivative Securities”). Each Seller’s pro rata percentage of the Exchange Consideration is equal to the ratio of the aggregate number of GEDi Cube Shares owned by such Seller divided by the aggregate number of GEDi Cube Shares issued and outstanding, in each case, as of the Closing Date. The transaction was accounted for in accordance with the provisions of ASC 805-10 - Business Combinations The assets acquired and liabilities assumed were initially recognized provisionally in the accompanying consolidated balance sheets at their estimated fair values as of the acquisition date. The fair values as of the acquisition date are based on information that existed as of the acquisition date. The Company completed its accounting for this acquisition during the period ended June 30, 2024. As a result of the completion of the Company’s analysis, the amount of in-process research and development was determined to have a value of nil. Accordingly, the amount of goodwill recognized was increased to include the previously recognized amount of in-process research and development. There was no impact to the Company’s consolidated statement of operations as a result of this change to the allocation. The acquisition-date fair value of the consideration transferred totaled approximately $ 156.6 Schedule of acquisition date fair value Common stock $ 136,001,631 Contingent consideration 20,557,500 Total consideration transferred $ 156,559,131 The fair value of the Company’s common shares issued as consideration was based on the closing price of the Company’s common stock as of the Acquisition Date. The fair value of the contingent consideration The following table details the fair values of the assets acquired and liabilities assumed at the acquisition date: Schedule of fair value of assets acquired and liabilities assumed Cash $ 65,851 Prepaid & Other Assets 151,544 Fixed Assets 16,243 Operating lease ROU 624,366 Total Assets Acquired: 858,004 Accounts Payable 583,577 Accrued Expenses 722,508 Operating Lease liability 624,367 Notes Payable 1,832,460 Total Liabilities Assumed 3,762,913 Net Assets Acquired (2,904,909 ) Goodwill 159,464,040 Total Consideration $ 156,559,131 The goodwill recognized is attributable primarily to expected synergies and the assembled workforce of Gedi Cube. None of the goodwill is expected to be deductible for income tax purposes. The fair values of the acquired tangible and intangible assets were determined using variations of the income approach. The income approach valuation methodology used for the intangible assets acquired makes use of Level 3 inputs. The Company recognized approximately $ 1.2 The amounts of revenue and loss of GEDi Cube, included in the Company’s consolidated statements of operations from the Closing Date through June 30, 2024 are as follows: Schedule of consolidated statements of operations Revenues $ — Net loss $ (1,243,144 ) Consolidated unaudited pro forma information: The following consolidated pro forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2023 for the statement of operations for the twelve-month period ended June 30, 2024. These amounts have been estimated after applying the Company’s accounting policies: Schedule of consolidated proforma information Revenues $ — Net loss $ (83,571,822 ) The following consolidated pro forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2022 for the statement of operations for the twelve-month period ended June 30, 2023. These amounts have been estimated after applying the Company’s accounting policies: Revenues $ — Net loss $ (42,490,305 )

SEGMENT REPORTING

SEGMENT REPORTING	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE 13 — SEGMENT REPORTING Beginning with the year ended June 30, 2024, the Company has two reportable segments. Prior to the year ended June 30, 2024, the Company had only a single reportable segment, the acquisition and integration of Renovaro Cube resulted in the identification of a separate reportable segment by the Company's chief operating decision maker. These segments have different strategic and economic goals and are managed separately because they require different technology and marketing strategies. Reportable Segment Description RENB Developing new immunotherapies to combat cancer RENC Developing a predicative artificial intelligence based diagnostic methodology for the use of earlier cancer detection The Company’s chief executive officer is the chief operating decision maker and reviews the internal management reports for each segment at least quarterly. During the year ended June 30, 2024, there were no significant inter-company revenues or expenses. The chief operating decision maker assesses performance for each segment and decides how to allocate resources based on segment operating losses that also is reported on the consolidated statement of operations. The measure of segment assets is reported on the balance sheet as total consolidated assets. The accounting policies of each segment are the same as those described in the summary of significant accounting policies. Schedule of segment operating loss and asset information Operating loss Assets United States $ 80,470,579 $ 2,998,311 Netherlands 1,168,716 160,131,139 $ 81,639,296 $ 163,129,450 The chief operating decision maker uses loss from operations to evaluate the performance of each segment’s assets in deciding how to allocate available capital between segments. The chief operating decision maker also uses loss from operations in their competitive analysis by benchmarking the Company’s competitors. The competitive analysis along with the monitoring of budgeted versus actual results are used in assessing the performance of the segment. Information regarding each reportable segment for the year ended June 30, 2024 is as follows: Schedule of information regarding segment reporting RENB RENC Total General and administrative $ 23,449,158 $ 1,108,449 $ 24,557,608 Research and development 2,651,971 56,858 2,708,829 Intangible asset impairment 42,611,000 — 42,611,000 Goodwill impairment 11,640,000 — 11,640,000 Depreciation and amortization 118,450 3,409 121,859 Segment operating loss $ 80,470,579 $ 1,168,716 $ 81,639,296 Geographic information: RENB and RENC are managed on a worldwide basis but operate in offices located in the United Stated and the Netherlands, respectively. The geographic information analyses the Company's operations and assets based on the country in which each segment operates. In presenting this geographic information, segment operating results have been based on the geographic location in which the services were provided to the segment and segment assets were based on the geographic location of the assets.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 — SUBSEQUENT EVENTS Related to the June 14, 2024, Private Placement, ranging from July 3, 2024, to October 2, 2024, the Company sold 1,525,316 1.4726 2,246,181 On August 1, 2024, the Company issued 2,000,000 1,400,000 On August 23, 2024, the Company forfeited 833,333 1,000,000 978,261 0.69

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Business	Business –
Basis of Presentation	Basis of Presentation
Principles of Consolidation	Principles of Consolidation
Subsidiaries	Subsidiaries Renovaro Biosciences Denmark ApS (“Renovaro Denmark”), formerly Enochian Biosciences Denmark ApS a Danish corporation was incorporated on April 1, 2001. On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement, the Company acquired Renovaro Denmark and it became a 100% owned subsidiary of Renovaro subject to 185,053 shares of Common Stock of Renovaro held in escrow according to Danish law (the “Escrow Shares”). As of June 30, 2024, there are 17,414 On February 13, 2024, the Company acquired 100
Use of Accounting Estimates	Use of Accounting Estimates
Functional Currency and Foreign Currency Translation	Functional Currency and Foreign Currency Translation
Cash and Cash Equivalents	Cash and Cash Equivalents
Concentration of Credit Risk	Concentration of Credit Risk
Insurance Receivable	Insurance Receivable
Property and Equipment	Property and Equipment
Intangible Assets	Intangible Assets Definite life intangible assets relate to patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 350, Goodwill and Other Intangible Assets Indefinite life intangible assets include license agreements and goodwill acquired in a business combination. The Company accounts for indefinite life intangible assets in accordance with ASC 350. License agreement costs represent the fair value of the license agreement on the date acquired and are tested annually for impairment on June 30 or whenever events or changes in circumstances indicate the fair value of the license is less than the carrying amount.
Goodwill	Goodwill
Impairment of Goodwill and Indefinite Lived Intangible Assets	Impairment of Goodwill and Indefinite Lived Intangible Assets For indefinite life intangible assets, such as IPR&D, on an annual basis on June 30th we determine the fair value of the asset and record an impairment loss, if any, for the excess of the carrying value of the asset over its fair value. For the year ended June 30, 2023, the carrying value of the IPR&D exceeded its fair value. Therefore, the Company recorded an impairment loss of $18,960,000 during the year ended June 30, 2023. During the year ended June 30, 2024, the Company recorded an impairment loss of $42,611,000 related to the termination of the license agreement with Weird Science LLC (see Note 5.) The carrying value of IPR&D and goodwill at June 30, 2024, were zero 0 159,330,161
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use are their respective fair values. No
Leases	Leases Rent expense for operating leases is recognized on a straight-line basis, unless the operating lease right-of-use assets have been impaired, over the reasonably assured lease term based on the total lease payments and is included in general and administrative expenses in the consolidated statements of operations. For operating leases that reflect impairment, the Company will recognize the amortization of the operating lease right-of-use assets on a straight-line basis over the remaining lease term with rent expense still included in general and administrative expenses in the consolidated statements of operations.
Research and Development Expenses	Research and Development Expenses 2,708,829 4,165,197
Income Taxes	Income Taxes
Loss Per Share	Loss Per Share 152,837,573 63,698,144 17,146,315 7,949,513
Fair Value of Financial Instruments	Fair Value of Financial Instruments Level 3 liabilities held as of June 30, 2024, consisted of a contingent consideration liability related to the February 13, 2024, acquisition of Renovaro Cube
Stock-Based Compensation	Stock-Based Compensation FASB ASC Topic 718, Compensation – Stock Compensation 4,673,129 3,535,051 . The Company recognizes compensation costs for stock option awards to employees, officers and directors based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average assumptions used to estimate the fair value of the stock options granted using the Black-Scholes option-pricing model are the expected term of the award, the underlying stock price volatility, the risk-free interest rate, and the expected dividend yield. The Company accounts for forfeitures as they occur. The Company records stock-based compensation for services received from non-employees in accordance with ASC 718, Compensation—Stock Compensation Non-Employees The Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior. Accordingly, the Company has elected to use the “simplified method” to estimate the expected term of its share-based awards. The simplified method computes the expected term as the sum of the award’s vesting term plus the original contractual term divided by two.
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of key input to valuing the contingent consideration liability	Schedule of key input to valuing the contingent consideration liability Stock Price $ 1.75 Exercise Price $ 0.46 8.23 Volatility 109 145 Risk Free Rate 4.24 5.21 Expected Dividends 0 % Discount Rate (Monte-Carlo model only) 0 % Expected Term (years) 0.47 9.50 At initial recognition of the contingent consideration, the inputs were: Stock Price $ 1.92 Exercise Price $ 0.46 4.50 Volatility 107 133 Risk Free Rate 4.22 5.14 Expected Dividends 0 % Discount Rate (Monte-Carlo model only) 12 % Expected Term (years) 0.56 9.88
Schedule of fair value measurement on recurring basis	Schedule of fair value measurement on recurring basis Fair Value Measurements at Quoted Prices in Significant Other Significant Other Unobservable Inputs (Level 1) (Level 2) (Level 3) The roll forward of the contingent consideration liability is as follows: Balance June 30, 2023 — — $ — Contingent consideration in Acquisition — — 20,557,500 Settlements: contingent shares to be issued — — (3,520,027 ) Fair value adjustment — — (4,727,473 ) Contingent Consideration Liability at June 30, 2024 — — $ 12,310,000

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Schedule of property and equipment Useful Life June 30, 2024 June 30, 2023 Lab equipment and instruments 4 7 $ 639,998 $ 576,298 Leasehold improvements 10 224,629 224,629 Furniture, fixtures, and equipment 4 7 195,834 172,861 Total 1,060,461 973,788 Less accumulated depreciation (578,340 ) (464,799 ) Net Property and Equipment $ 482,121 $ 508,989

INTANGIBLE ASSETS AND GOODWILL

INTANGIBLE ASSETS AND GOODWILL (Tables)	12 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of definite-life and indefinite-life intangible assets	Schedule of definite-life and indefinite-life intangible assets Useful Life June 30, 2023 Additions Amortization Impairment Translation Adjustment June 30, 2024 Definite Life Intangible Assets Patents 20 $ 290,936 $ — $ — $ — $ (5,959 ) $ 284,977 Less Accumulated Amortization (251,260 ) — (8,296 ) — 4,622 (254,934 ) Net Definite-Life Intangible Assets $ 39,676 $ — $ (8,296 ) $ — $ (1,337 ) $ 30,043 Indefinite Life Intangible Assets and Goodwill Goodwill 11,640,000 159,464,039 — (11,640,000 ) (133,878 ) 159,330,161 IPR&D 42,611,000 — — (42,611,000 ) — — Total Indefinite Life Intangible Assets and Goodwill $ 54,251,000 $ 159,464,039 $ — $ (54,251,000 ) $ (133,878) $ 159,330,161 Useful Life June 30, 2022 Period Change Effect of Currency Translation June 30, 2023 Definite Life Intangible Assets Patents 20 $ 279,257 $ — 11,679 $ 290,936 Less Accumulated Amortization (234,989 ) (6,175 ) (10,096 ) (251,260 ) Net Definite-Life Intangible Assets $ 44,268 $ (6,175 ) $ 1,583 $ 39,676 Indefinite Life Intangible Assets License Agreement $ 61,571,000 $ (18,960,000 ) $ — $ 42,611,000 Goodwill 11,640,000 — — 11,640,000 Total Indefinite Life Intangible Assets $ 73,211,000 $ (18,960,000 ) $ — $ 54,251,000
Schedule of expected future amortization expense	Schedule of expected future amortization expense Years ended June 30, 2025 $ 7,511 2026 7,511 2027 7,511 2028 7,510 Total $ 30,043

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Jun. 30, 2024
Leases
Schedule of lease commitments	Schedule of lease commitments Years Ending June 30 Lease Expense 2025 $ 554,453 2026 457,876 2027 334,788 Thereafter 79,830 Less imputed interest (91,005 ) Total $ 1,335,942
Schedule of net operating lease expenses	Schedule of net operating lease expenses Years ended June 30, 2024 2023 Operating Lease Expense $ 383,549 $ 322,447 Sub-lease Income — (352,700 ) Total Net Lease Expense $ 383,549 $ (30,253 )

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	June 30 2024 2023 Excess of tax over book depreciation of fixed assets $ 8,258 $ 8,258 Excess of tax over book depreciation of patents 8,415 8,415 Stock/options compensation 6,672,252 3,885,996 Depreciation and amortization 188,422 152,059 Net operating loss carryforwards 144,191,530 140,547,314 Impairment expense 16,188,497 — Contingent consideration fair value 1,410,678 — Change in tax rate — — Valuation allowance (168,668,052 ) (144,602,042 ) Total Deferred Tax Assets (Liabilities) $ — $ —
Schedule of reconciliation of income tax expense	Schedule of reconciliation of income tax expense Years ended June 30, 2024 2023 Computed tax at expected statutory rate $ (24,066,011 ) $ (70,341,751 ) Non-US income taxed at different rates — — Non-deductible expenses / other items — — Valuation allowance 24,066,011 70,341,751 Income Tax Expense (Benefit) $ — $ —
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Years ended June 30, 2024 2023 Current Income Tax Expense Danish income tax (benefit) $ — $ — Total Current Tax Expense (Benefit) $ — $ — Deferred Income Tax Expense (Benefit) Excess of tax over book depreciation of fixed assets $ 8,258 $ 8,258 Excess of tax over book depreciation of patents 8,415 8,415 Stock/options compensation 6,672,252 3,885,996 Depreciation and amortization 188,422 152,059 Net operating loss carryforwards 144,191,530 140,547,314 Impairment expense 16,188,497 — Contingent consideration fair value 1,410,678 Change in tax rate — — Change in the valuation allowance (168,668,052 ) (144,602,042 ) Total Deferred Tax Expense $ — $ —

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	12 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted	Schedule of weighted-average assumptions used to estimate the fair values of the stock options granted Renovaro Inc. Expected term (in years) 5.0 6.5 Volatility 84.33 114.88 % Risk free interest rate 3.12 4.83 % Dividend yield 0 %
Schedule of stock options outstanding	Schedule of stock options outstanding Options Outstanding Options Exercisable Exercise Price Ranges Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 0.45 4.50 5,244,987 7.38 $ 1.89 3,817,105 7.15 $ 1.92 $ 4.51 6.50 167,634 6.48 $ 5.33 135,376 5.81 $ 5.49 $ 6.51 12.00 115,231 4.66 $ 7.63 111,585 4.57 $ 7.61 Total 5,527,852 7.29 $ 2.11 4,064,066 7.03 $ 2.20
Schedule of stock option activity	Schedule of stock option activity Shares Weighted Average Exercise Average Remaining Life Weighted Average Intrinsic Outstanding at June 30, 2023 4,401,211 $ 4.78 7.82 $ — Granted 4,983,572 $ 1.94 Exercised — $ — Forfeited — $ — Expired/Canceled (3,856,931 ) $ 4.94 Outstanding at June 30, 2024 5,527,852 $ 2.11 7.30 $ — Exercisable at June 30, 2024 4,064,066 $ 2.20 7.05 $ 525,943
Schedule of common stock purchase warrants outstanding	Schedule of common stock purchase warrants outstanding Warrants Outstanding Warrants Exercisable Exercise Price Number Outstanding Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (years) Weighted Average Exercise Price $ 0.53 471,698 1.33 471,698 1.33 $ 0.65 741,274 3.07 741,274 3.07 $ 1.14 1,189,036 3.73 1,189,036 3.73 $ 1.47 642,128 4.96 642,128 4.96 $ 1.48 50,740 4.99 50,740 4.99 Total 3,094,876 3.48 $ 1.00 3,094,876 3.48 $ 1.00
Schedule of warrants outstanding	Schedule of warrants outstanding Shares Weighted Average Exercise Weighted Average Remaining Outstanding at June 30, 2023 3,548,302 $ 0.73 4.80 Granted 3,497,918 $ 0.81 4.27 Exercised (3,951,344 ) $ 0.59 — Cancelled/Expired — $ — — Outstanding and exercisable at June 30, 2024 3,094,876 $ 1.00 3.48

ACQUISITION (Tables)

ACQUISITION (Tables)	12 Months Ended
	Jun. 30, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of acquisition date fair value	Schedule of acquisition date fair value Common stock $ 136,001,631 Contingent consideration 20,557,500 Total consideration transferred $ 156,559,131
Schedule of fair value of assets acquired and liabilities assumed	Schedule of fair value of assets acquired and liabilities assumed Cash $ 65,851 Prepaid & Other Assets 151,544 Fixed Assets 16,243 Operating lease ROU 624,366 Total Assets Acquired: 858,004 Accounts Payable 583,577 Accrued Expenses 722,508 Operating Lease liability 624,367 Notes Payable 1,832,460 Total Liabilities Assumed 3,762,913 Net Assets Acquired (2,904,909 ) Goodwill 159,464,040 Total Consideration $ 156,559,131
Schedule of consolidated statements of operations	Schedule of consolidated statements of operations Revenues $ — Net loss $ (1,243,144 )
Schedule of consolidated proforma information	Schedule of consolidated proforma information Revenues $ — Net loss $ (83,571,822 ) The following consolidated pro forma information assumes that the acquisition of Renovaro Cube took place on July 1, 2022 for the statement of operations for the twelve-month period ended June 30, 2023. These amounts have been estimated after applying the Company’s accounting policies: Revenues $ — Net loss $ (42,490,305 )

SEGMENT REPORTING (Tables)

SEGMENT REPORTING (Tables)	12 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of segment operating loss and asset information	Schedule of segment operating loss and asset information Operating loss Assets United States $ 80,470,579 $ 2,998,311 Netherlands 1,168,716 160,131,139 $ 81,639,296 $ 163,129,450
Schedule of information regarding segment reporting	Schedule of information regarding segment reporting RENB RENC Total General and administrative $ 23,449,158 $ 1,108,449 $ 24,557,608 Research and development 2,651,971 56,858 2,708,829 Intangible asset impairment 42,611,000 — 42,611,000 Goodwill impairment 11,640,000 — 11,640,000 Depreciation and amortization 118,450 3,409 121,859 Segment operating loss $ 80,470,579 $ 1,168,716 $ 81,639,296

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Feb. 13, 2024
Restructuring Cost and Reserve [Line Items]
Escrow shares remaining	17,414
In-process research and development	$ 0
Goodwill	159,330,161	$ 11,640,000
Impairment of assets	0	0
Research and development expense	$ 2,708,829	$ 4,165,197
Common stock outstanding	152,837,573	63,698,144
Anti-dilutive shares	17,146,315	7,949,513
Stock based compensation costs	$ 4,673,129	$ 3,535,051
Options Held [Member] | Employees, Officers, Directors and Consultants [Member]
Restructuring Cost and Reserve [Line Items]
Stock based compensation costs	4,673,129	3,535,051
Restricted Stock Units (RSUs) [Member] | Employees, Officers, Directors and Consultants [Member]
Restructuring Cost and Reserve [Line Items]
Stock based compensation costs	$ 4,673,129	$ 3,535,051
Renovaro Cube [Member]
Restructuring Cost and Reserve [Line Items]
Acquisition percentage			100%

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net loss	$ 80,650,172	$ 39,684,056
Cash and cash equivalents	220,467	1,874,480
Accumulated deficit	324,679,425	$ 244,029,253
Working capital deficit	$ 28,312,274

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details)	12 Months Ended
	Jun. 30, 2024 $ / shares
Black Scholes Option Pricing Model [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock Price	$ 1.75
Expected Dividends	0%
Discount Rate (Monte-Carlo model only)	0%
Black Scholes Option Pricing Model [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise Price	$ 0.46
Volatility	109%
Risk Free Rate	4.24%
Expected Term (years)	5 months 19 days
Black Scholes Option Pricing Model [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise Price	$ 8.23
Volatility	145%
Risk Free Rate	5.21%
Expected Term (years)	9 years 6 months
Initial Recognition [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Stock Price	$ 1.92
Expected Dividends	0%
Discount Rate (Monte-Carlo model only)	12%
Initial Recognition [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise Price	$ 0.46
Volatility	107%
Risk Free Rate	4.22%
Expected Term (years)	6 months 21 days
Initial Recognition [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Exercise Price	$ 4.50
Volatility	133%
Risk Free Rate	5.14%
Expected Term (years)	9 years 10 months 17 days

FAIR VALUE MEASUREMENTS (Deta_2

FAIR VALUE MEASUREMENTS (Details 1)	12 Months Ended
	Jun. 30, 2024 USD ($)
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance June 30, 2023	$ 0
Contingent consideration in Acquisition	0
Settlements: contingent shares to be issued	0
Fair value adjustment	0
Contingent Consideration Liability at June 30, 2024	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance June 30, 2023	0
Contingent consideration in Acquisition	0
Settlements: contingent shares to be issued	0
Fair value adjustment	0
Contingent Consideration Liability at June 30, 2024	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Balance June 30, 2023	0
Contingent consideration in Acquisition	20,557,500
Settlements: contingent shares to be issued	(3,520,027)
Fair value adjustment	(4,727,473)
Contingent Consideration Liability at June 30, 2024	$ 12,310,000

FAIR VALUE MEASUREMENTS (Deta_3

FAIR VALUE MEASUREMENTS (Details Narrative) - Renovaro Cube [Member] - USD ($)		12 Months Ended
	Feb. 13, 2024	Jun. 30, 2024
Restructuring Cost and Reserve [Line Items]
Contingent shares issuable in connection with the acquisition		7,613,301
Contingent consideration liability was recorded at fair value	$ 20,557,500
Common Stock [Member]
Restructuring Cost and Reserve [Line Items]
Contingent shares issuable in connection with the acquisition	70,834,183

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Line Items]
Total	$ 1,060,461	$ 973,788
Less Accumulated Depreciation	(578,340)	(464,799)
Net Property and Equipment	482,121	508,989
Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Total	$ 639,998	576,298
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Life	10 years
Total	$ 224,629	224,629
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total	$ 195,834	$ 172,861
Minimum [Member] | Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Minimum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful Life	4 years
Maximum [Member] | Lab Equipment And Instruments [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years
Maximum [Member] | Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 113,563	$ 107,321

INTANGIBLE ASSETS AND GOODWIL_2

INTANGIBLE ASSETS AND GOODWILL (Details) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Finite-Lived Intangible Assets [Line Items]
Net definite-life intangible assets at beginning	$ 39,676	$ 44,268
Net definite-life intangible assets, Additions	0	(6,175)
Net definite-life intangible assets, Amortization	(8,296)
Net definite-life intangible assets, Impairment	0
Net definite-life intangible assets, Translation adjustment	(1,337)	1,583
Net definite-life intangible assets at ending	30,043	39,676
Total indefinite life intangible assets and goodwill at beginning	54,251,000	73,211,000
Total indefinite life intangible assets and goodwill, Additions	159,464,039	(18,960,000)
Total indefinite life intangible assets and goodwill, Amortization	0
Total indefinite life intangible assets and goodwill, Impairment	(54,251,000)
Total indefinite life intangible assets and goodwill, Translation adjustment	(133,878)	0
Total indefinite life intangible assets and goodwill at ending	$ 159,330,161	54,251,000
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life	20 years
Net definite-life intangible assets at beginning	$ 290,936	279,257
Net definite-life intangible assets, Additions	0	0
Net definite-life intangible assets, Amortization	0
Net definite-life intangible assets, Impairment	0
Net definite-life intangible assets, Translation adjustment	(5,959)	11,679
Net definite-life intangible assets at ending	284,977	290,936
Less Accumulated Amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Net definite-life intangible assets at beginning	(251,260)	(234,989)
Net definite-life intangible assets, Additions	0	(6,175)
Net definite-life intangible assets, Amortization	(8,296)
Net definite-life intangible assets, Impairment	0
Net definite-life intangible assets, Translation adjustment	4,622	(10,096)
Net definite-life intangible assets at ending	(254,934)	(251,260)
Goodwill [Member]
Finite-Lived Intangible Assets [Line Items]
Total indefinite life intangible assets and goodwill at beginning	11,640,000	11,640,000
Total indefinite life intangible assets and goodwill, Additions	159,464,039	0
Total indefinite life intangible assets and goodwill, Amortization	0
Total indefinite life intangible assets and goodwill, Impairment	(11,640,000)
Total indefinite life intangible assets and goodwill, Translation adjustment	(133,878)	0
Total indefinite life intangible assets and goodwill at ending	159,330,161	11,640,000
In Process Research and Development [Member]
Finite-Lived Intangible Assets [Line Items]
Total indefinite life intangible assets and goodwill at beginning	42,611,000	61,571,000
Total indefinite life intangible assets and goodwill, Additions	0	(18,960,000)
Total indefinite life intangible assets and goodwill, Amortization	0
Total indefinite life intangible assets and goodwill, Impairment	(42,611,000)
Total indefinite life intangible assets and goodwill, Translation adjustment	0	0
Total indefinite life intangible assets and goodwill at ending	$ 0	$ 42,611,000

INTANGIBLE ASSETS AND GOODWIL_3

INTANGIBLE ASSETS AND GOODWILL (Details 1) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2025	$ 7,511
2026	7,511
2027	7,511
2028	7,510
Total	$ 30,043	$ 39,676

INTANGIBLE ASSETS AND GOODWIL_4

INTANGIBLE ASSETS AND GOODWILL (Details Narrative) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Definite-life intangible assets	$ 30,043	$ 39,676
Amortization expense	8,296	6,175
Impairment adjustment	42,611,000	18,960,000
Goodwill impairment adjustment	$ 11,640,000	$ 0

LEASES (Details)

LEASES (Details)	Jun. 30, 2024 USD ($)
Leases
2025	$ 554,453
2026	457,876
2027	334,788
Thereafter	79,830
Less imputed interest	(91,005)
Total	$ 1,335,942

LEASES (Details 1)

LEASES (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Leases
Operating Lease Expense	$ 383,549	$ 322,447
Sub-lease Income	0	(352,700)
Total Net Lease Expense	$ 383,549	$ (30,253)

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($)					12 Months Ended
	Apr. 18, 2023	Jun. 20, 2022	Jun. 19, 2018	Nov. 13, 2017	Jun. 30, 2024	Jun. 30, 2023
Lease premises, description			On June 19, 2018, Renovaro entered into a Lease Agreement for a term of ten years from September 1, 2018, with Century City Medical Plaza Land Co., Inc., pursuant to which the Company agreed to lease approximately 2,453 rentable square feet. On February 20, 2019, Renovaro entered into an Addendum to the original Lease Agreement with an effective date of December 1, 2019, where it expanded the lease area to include another 1,101 square feet for a total rentable 3,554 square feet. The base rent increases by 3% each year, and ranges from $17,770 per month for the first year to $23,186 per month for the tenth year. The equalized monthly lease payment for the term of the lease is $20,050.	On November 13, 2017, Renovaro entered into a Lease Agreement for a term of five years and two months from November 1, 2017, with Plaza Medical Office Building, LLC, a California limited liability company, as landlord, (the “Landlord”) pursuant to which the Company agreed to lease from the Landlord approximately 2,325 rentable square feet. The base rent increased by 3% each year and ranged from approximately $8,719 per month for the first year to $10,107 per month for the two months of the sixth year. The lease was terminated early without penalties or additional costs as of September 30, 2022, that released an accrual of $70,800 related to leasehold improvements that was not utilized.
Weighted-average remaining term					2 years 6 months 14 days
Weighted-average discount rate					5.14%
Sublease agreement description		On June 20, 2022, the Company entered into a sublease Agreement with One Health Labs (the “Subtenant”), whereby the Subtenant agreed to lease 3,554 square feet of space currently rented by the Company in Century City Medical Plaza as of June 25, 2022, for a period of 3.5 years with an option to renew for the remaining term of the lease that ends as of June 19, 2028. The base rent was $17,770 per month plus $750 towards utility fees that are part of the original lease agreement and would increase by 3% each year over the term of the sublease. The Company received a total of $57,022 on July 1, 2022 after execution of the sublease to cover the first month rent, utility fee and deposit. The first sublease payment began on August 1, 2022.
Lease payment	$ 139,460
Security deposit	35,540
Termination fee	$ 175,000
Operating lease payments					$ 380,983	$ 439,519
Operating lease expense						322,447
Cash payments						439,519
Accrual payments related to the termination of lease						77,242
General and Administrative Expense [Member]
Lease expense					$ 383,549	$ 322,447

DEBT (Details Narrative)

DEBT (Details Narrative) - USD ($)

1 Months Ended

2 Months Ended

12 Months Ended

Jun. 14, 2024

Mar. 14, 2024

Feb. 16, 2024

Feb. 15, 2024

Feb. 05, 2024

Jan. 31, 2024

Jan. 12, 2024

Jan. 11, 2024

Jan. 02, 2024

Nov. 30, 2023

Nov. 22, 2023

Nov. 03, 2023

Jun. 26, 2023

Mar. 31, 2023

Dec. 30, 2022

Jul. 14, 2022

May 17, 2022

Mar. 30, 2020

Feb. 06, 2020

Dec. 29, 2023

Oct. 05, 2023

Jun. 04, 2024

Jun. 30, 2024

Jun. 30, 2023

Feb. 11, 2021

Debt Instrument [Line Items]

Common stock, par value

$ 0.0001

$ 0.0001

Warrant purchase price

$ 0.53

$ 1.14

Interest expense related to note balance

$ 245,000

Gross proceeds

3,770,512

$ 0

Stock issued for debt conversion

1,200,000

Proceeds from private placement

$ 1,000,000

$ 2,711,000

3,000,000

4,011,823

Other current liabilities

231,381

Total interest expense

1,011,322

580,344

Finance Agreement [Member]

Debt Instrument [Line Items]

Accrued interest expense

20,128

21,180

Monthly instalments amount

$ 77,127

Down payment amount

$ 235,000

870,073

1,121,767

Finance Agreement [Member] | Other Current Liabilities [Member]

Debt Instrument [Line Items]

Rate of interest

7.90%

Principal amount

$ 906,834

RS Bio [Member]

Debt Instrument [Line Items]

Principal amount

$ 105,263

Note interest rate

12%

Maturity date

Mar. 01, 2024

Warrant purchase price

$ 0.53

Gross proceeds

$ 100,000

Original issue discount promissory note percentage

5%

Amortization of debt discount

5,263

Interest rate

12%

Gross proceeds original issue discount rate

5%

Convertible Notes Payables [Member]

Debt Instrument [Line Items]

Principal amount

$ 600,000

Interest rate

6%

Amended And Restated Secured Notes [Member]

Debt Instrument [Line Items]

Maturity date

Feb. 28, 2024

Accrued interest amount

$ 30,302

Interest rate

12%

Issuance of shares

198,439

Shares issued for accrued interest

29,419

Prepayment shares

169,020

Share price

$ 1.03

Obligation value

$ 1,200,000

Number of shares issued, value

204,392

Prepaid interest

$ 174,090

Stock issued for debt conversion

$ 1,200,000

The Notes [Member]

Debt Instrument [Line Items]

Note interest rate

10%

Sale of stock, shares

1,424,862

Sale of stock, value

$ 2,098,252

Principal and interest accrued amount

$ 2,098,252

Sale of stock, price per share

$ 1.4726

RS Bio ApS [Member] | Bridge Loan [Member]

Debt Instrument [Line Items]

Net of debt discount

105,263

RS Bio ApS [Member] | Interest Expense [Member] | Bridge Loan [Member]

Debt Instrument [Line Items]

Amortization of debt discount

5,263

RS Bio ApS [Member] | Accrued Expenses [Member]

Debt Instrument [Line Items]

Accrued interest expense

6,316

Loan Agreement [Member] | Bridge Loan [Member]

Debt Instrument [Line Items]

Accrued interest expense

36,388

Interest expense related to note balance

0

Interest rate

10%

Promissory Note [Member]

Debt Instrument [Line Items]

Principal amount

$ 5,000,000

Maturity date

Nov. 30, 2023

Nov. 30, 2021

Interest rate

6%

Stock issued for debt conversion

$ 501,370

Stock issued for debt conversion, shares

188,485

Issuance of common stock

$ 299,178

$ 493,192

Rate of interest

6%

Number of shares issued

47,115

74,054

Market price

$ 298,178

Repayment on promissory note

$ 418,503

Promissory note balance, net of discount

824,418

Promissory Note [Member] | Subscription Agreements [Member]

Debt Instrument [Line Items]

Repayment on promissory note

100,440

Promissory Note [Member] | Subscription Agreements 1 [Member]

Debt Instrument [Line Items]

Repayment on promissory note

318,063

Promissory Note [Member] | Interest Expense [Member]

Debt Instrument [Line Items]

Amortization of debt discount

$ 393,763

$ 348,621

Note 2020 [Member]

Debt Instrument [Line Items]

Principal amount

418,503

Minimum [Member] | Promissory Note [Member]

Debt Instrument [Line Items]

Rate of interest

6%

Maximum [Member] | Promissory Note [Member]

Debt Instrument [Line Items]

Rate of interest

12%

Private Placement [Member]

Debt Instrument [Line Items]

Sale of stock, shares

2,325,869

Sale of stock, value

$ 3,425,075

Warrant purchase price

$ 0.53

Share price

$ 0.0001

Sale of stock, price per share

$ 1.4726

Number of shares issued

567,588

Warrants purchased

283,794

Proceeds from private placement

$ 300,822

Warrant [Member] | Amended And Restated Secured Notes [Member]

Debt Instrument [Line Items]

Stock issued for debt conversion, shares

1,132,075

Common Stock [Member]

Debt Instrument [Line Items]

Shares issued for accrued interest

198,439

Issuance of common stock

$ 1,625,000

Number of shares issued

4,718,532

2,378,070

Proceeds from private placement

$ 1,300,823

Common Stock [Member] | Bridge Loan [Member]

Debt Instrument [Line Items]

Principal amount

$ 665,387

Sale of stock, shares

454,708

Sale of stock, value

$ 100,400

March Note 2024 [Member]

Debt Instrument [Line Items]

Principal amount

$ 500,000

Note interest rate

10%

Maturity date

Mar. 15, 2025

Accrued interest expense

$ 12,361

Interest expense related to note balance

0

March Note 2024 [Member] | Warrant [Member]

Debt Instrument [Line Items]

Warrant purchase price

$ 1.4726

March Note 2024 [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Sale of stock, shares

344,966

Common stock, par value

$ 0.0001

Sale of stock, value

$ 512,361

January Note 2024 [Member]

Debt Instrument [Line Items]

Principal amount

$ 125,000

$ 460,000

Note interest rate

12%

Maturity date

Dec. 29, 2024

Jan. 11, 2025

Accrued interest expense

67,013

Interest expense related to note balance

125,000

Conversion price

$ 3.38

$ 3.38

Gross proceeds

$ 125,000

Bear interest percentage

12%

Principal outstanding balance

125,000

January Note 2024 [Member] | Bridge Loan [Member]

Debt Instrument [Line Items]

Net of debt discount

526,315

January Note 2024 [Member] | Interest Expense [Member] | Bridge Loan [Member]

Debt Instrument [Line Items]

Amortization of debt discount

26,315

January Note 2024 [Member] | Accrued Expenses [Member]

Debt Instrument [Line Items]

Accrued interest expense

31,579

January Note 2024 [Member] | RS Bio [Member]

Debt Instrument [Line Items]

Principal amount

$ 526,315

Maturity date

Mar. 01, 2024

Gross proceeds

$ 500,000

Original issue discount promissory note percentage

5%

Amortization of debt discount

26,315

Interest rate

12%

Gross proceeds original issue discount rate

5%

January Note 2024 [Member] | Warrant [Member]

Debt Instrument [Line Items]

Warrant purchase price

$ 1.4726

January Note 2024 [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Sale of stock, shares

325,508

Common stock, par value

$ 0.0001

Sale of stock, value

$ 483,460

December Note 2023 [Member]

Debt Instrument [Line Items]

Principal amount

$ 560,000

Accrued interest expense

67,013

Interest expense related to note balance

120,000

Conversion price

$ 3.38

Bear interest percentage

12%

Principal outstanding balance

120,000

December Note 2023 [Member] | Private Placement [Member]

Debt Instrument [Line Items]

Gross proceeds

$ 560,000

December Note 2023 [Member] | Private Placement 1 [Member]

Debt Instrument [Line Items]

Gross proceeds

440,000

December Note 2023 [Member] | Private Placement 2 [Member]

Debt Instrument [Line Items]

Gross proceeds

$ 100,000

December Note 2023 [Member] | Private Placement 3 [Member]

Debt Instrument [Line Items]

Gross proceeds

$ 20,000

December Note 2023 [Member] | Warrant [Member]

Debt Instrument [Line Items]

Warrant purchase price

$ 1.4726

December Note 2023 [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Principal amount

$ 440,000

Sale of stock, shares

317,715

Common stock, par value

$ 0.0001

Sale of stock, value

$ 66,000

Accrued interest amount

28,453

Note 2023 [Member]

Debt Instrument [Line Items]

Principal amount

$ 2,105,263

Note interest rate

12%

Maturity date

Sep. 05, 2024

Accrued interest expense

189,614

Interest expense related to note balance

0

Conversion price

$ 3.38

Gross proceeds

$ 2,000,000

Principal outstanding balance

$ 0

Original issue discount promissory note percentage

5%

Original issue discount percentage

5%

Discount accreted

$ 105,263

Common stock and received gross proceeds

$ 10,000,000

Offering price per share percentage

95%

Floor price per share

$ 4.50

Amortization of debt discount

78,567

Discount amortization to other income and expense

26,696

Note 2023 [Member] | Warrant [Member] | Minimum [Member]

Debt Instrument [Line Items]

Warrant purchase price

$ 1.4726

Note 2023 [Member] | Warrant [Member] | Maximum [Member]

Debt Instrument [Line Items]

Warrant purchase price

$ 1.4765

Note 2023 [Member] | Common Stock [Member]

Debt Instrument [Line Items]

Principal amount

$ 2,293,825

Sale of stock, shares

1,546,449

Common stock, par value

$ 0.0001

Sale of stock, value

$ 443,575

Other Notes Payable

$ 318,063

November 2023 Note [Member]

Debt Instrument [Line Items]

Accrued interest expense

69,083

Amortization of debt discount

50,000

Net of debt discount

$ 750,000

Number of warrants exercised

471,699

Warrant exercise price per share

$ 0.53

Exercise warrants amount

$ 250,000

November 2023 Note [Member] | RS Bio [Member]

Debt Instrument [Line Items]

Principal amount

$ 1,000,000

Maturity date

Mar. 01, 2024

Jan. 01, 2024

Gross proceeds

$ 950,000

Original issue discount promissory note percentage

5%

Discount accreted

$ 50,000

Interest rate

12%

Gross proceeds original issue discount rate

5%

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Excess of tax over book depreciation of fixed assets	$ 8,258	$ 8,258
Excess of tax over book depreciation of patents	8,415	8,415
Stock/options compensation	6,672,252	3,885,996
Depreciation and amortization	188,422	152,059
Net operating loss carryforwards	144,191,530	140,547,314
Impairment expense	16,188,497	0
Contingent consideration fair value	1,410,678	0
Change in tax rate	0	0
Valuation allowance	(168,668,052)	(144,602,042)
Total Deferred Tax Assets (Liabilities)	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Computed tax at expected statutory rate	$ (24,066,011)	$ (70,341,751)
Non-US income taxed at different rates	0	0
Non-deductible expenses / other items	0	0
Valuation allowance	24,066,011	70,341,751
Income Tax Expense (Benefit)	$ 0	$ 0

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Current Income Tax Expense
Danish income tax (benefit)	$ 0	$ 0
Total Current Tax Expense (Benefit)	0	0
Deferred Income Tax Expense (Benefit)
Excess of tax over book depreciation of fixed assets	8,258	8,258
Excess of tax over book depreciation of patents	8,415	8,415
Stock/options compensation	6,672,252	3,885,996
Depreciation and amortization	188,422	152,059
Net operating loss carryforwards	144,191,530	140,547,314
Impairment expense	16,188,497	0
Contingent consideration fair value	1,410,678
Change in tax rate	0	0
Change in the valuation allowance	(168,668,052)	(144,602,042)
Total Deferred Tax Expense	$ 0	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - United States Tax [Member] - USD ($)	Jun. 30, 2024	Jun. 30, 2023
Effective Income Tax Rate Reconciliation [Line Items]
Operating loss carryforwards	$ 489,177,759	$ 476,965,239
Deferred tax assets	$ 144,191,530	$ 140,547,314

STOCKHOLDERS' EQUITY (Details)

STOCKHOLDERS' EQUITY (Details) - Renovaro [Member]	12 Months Ended
	Jun. 30, 2024
Dividend yield	0%
Minimum [Member]
Expected term (in years)	5 years
Volatility	84.33%
Risk free interest rate	3.12%
Maximum [Member]
Expected term (in years)	6 years 6 months
Volatility	114.88%
Risk free interest rate	4.83%

STOCKHOLDERS' EQUITY (Details 1

STOCKHOLDERS' EQUITY (Details 1) - Share-Based Payment Arrangement, Option [Member]	12 Months Ended
	Jun. 30, 2024 $ / shares shares
Option Indexed to Issuer's Equity [Line Items]
Number share option outstanding | shares	5,527,852
Options Outstanding, Weighted Average Remaining Contractual Life (years)	7 years 3 months 14 days
Options Outstanding, Weighted Average Exercise Price	$ 2.11
Options Exercisable | shares	4,064,066
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 10 days
Options Exercisable, Weighted Average Exercise Price	$ 2.20
Exercise Price Range 1 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices, Lower	0.45
Exercise Prices, Upper	$ 4.50
Number share option outstanding | shares	5,244,987
Options Outstanding, Weighted Average Remaining Contractual Life (years)	7 years 4 months 17 days
Options Outstanding, Weighted Average Exercise Price	$ 1.89
Options Exercisable | shares	3,817,105
Options Exercisable, Weighted Average Remaining Contractual Life (years)	7 years 1 month 24 days
Options Exercisable, Weighted Average Exercise Price	$ 1.92
Exercise Price Range 2 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices, Lower	4.51
Exercise Prices, Upper	$ 6.50
Number share option outstanding | shares	167,634
Options Outstanding, Weighted Average Remaining Contractual Life (years)	6 years 5 months 23 days
Options Outstanding, Weighted Average Exercise Price	$ 5.33
Options Exercisable | shares	135,376
Options Exercisable, Weighted Average Remaining Contractual Life (years)	5 years 9 months 21 days
Options Exercisable, Weighted Average Exercise Price	$ 5.49
Exercise Price Range 3 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices, Lower	6.51
Exercise Prices, Upper	$ 12
Number share option outstanding | shares	115,231
Options Outstanding, Weighted Average Remaining Contractual Life (years)	4 years 7 months 28 days
Options Outstanding, Weighted Average Exercise Price	$ 7.63
Options Exercisable | shares	111,585
Options Exercisable, Weighted Average Remaining Contractual Life (years)	4 years 6 months 25 days
Options Exercisable, Weighted Average Exercise Price	$ 7.61

STOCKHOLDERS' EQUITY (Details 2

STOCKHOLDERS' EQUITY (Details 2) - Employee Stock Options [Member] - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Option Indexed to Issuer's Equity [Line Items]
Options Outstanding at beginning of period	4,401,211
Weighted Average Exercise Price, Outstanding at beginning of period	$ 4.78
Weighted Average remaining life	7 years 3 months 18 days	7 years 9 months 25 days
Weighted Average Intrinsic Value, Outstanding at beginning of period	$ 0
Granted	4,983,572
Weighted average exercise price, Granted	$ 1.94
Exercised	0
Weighted average exercise price, Exercised	$ 0
Forfeited	0
Weighted Average Exercise Price, Forfeited	$ 0
Cancelled/Expired	(3,856,931)
Weighted Average Exercise Price, Expired	$ 4.94
Options Outstanding at end of period	5,527,852	4,401,211
Weighted Average Exercise Price, Outstanding at ending of period	$ 2.11	$ 4.78
Weighted Average Intrinsic Value, Outstanding at end of period	$ 0	$ 0
Options Exercisable	4,064,066
Weighted Average Exercise Price, Exercisable at ending of period	$ 2.20
Weighted Average Remaining Life, Exercisable	7 years 18 days
Weighted Average Intrinsic Value, Exercisable end of period	$ 525,943

STOCKHOLDERS' EQUITY (Details 3

STOCKHOLDERS' EQUITY (Details 3) - Common Stock Purchase Warrants [Member]	12 Months Ended
	Jun. 30, 2024 $ / shares shares
Option Indexed to Issuer's Equity [Line Items]
Number share option outstanding	3,094,876
Options Outstanding, Weighted Average Remaining Contractual Life (years)	3 years 5 months 23 days
Options Exercisable	3,094,876
Options Exercisable, Weighted Average Remaining Contractual Life (years)	3 years 5 months 23 days
Options Outstanding, Weighted Average Exercise Price | $ / shares	$ 1
Options Exercisable, Weighted Average Exercise Price | $ / shares	1
Exercise Price Range 1 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices | $ / shares	$ 0.53
Number share option outstanding	471,698
Options Outstanding, Weighted Average Remaining Contractual Life (years)	1 year 3 months 29 days
Options Exercisable	471,698
Options Exercisable, Weighted Average Remaining Contractual Life (years)	1 year 3 months 29 days
Exercise Price Range 2 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices | $ / shares	$ 0.65
Number share option outstanding	741,274
Options Outstanding, Weighted Average Remaining Contractual Life (years)	3 years 25 days
Options Exercisable	741,274
Options Exercisable, Weighted Average Remaining Contractual Life (years)	3 years 25 days
Exercise Price Range 3 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices | $ / shares	$ 1.14
Number share option outstanding	1,189,036
Options Outstanding, Weighted Average Remaining Contractual Life (years)	3 years 8 months 23 days
Options Exercisable	1,189,036
Options Exercisable, Weighted Average Remaining Contractual Life (years)	3 years 8 months 23 days
Exercise Price Range 4 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices | $ / shares	$ 1.47
Number share option outstanding	642,128
Options Outstanding, Weighted Average Remaining Contractual Life (years)	4 years 11 months 15 days
Options Exercisable	642,128
Options Exercisable, Weighted Average Remaining Contractual Life (years)	4 years 11 months 15 days
Exercise Price Range 5 [Member]
Option Indexed to Issuer's Equity [Line Items]
Exercise Prices | $ / shares	$ 1.48
Number share option outstanding	50,740
Options Outstanding, Weighted Average Remaining Contractual Life (years)	4 years 11 months 26 days
Options Exercisable	50,740
Options Exercisable, Weighted Average Remaining Contractual Life (years)	4 years 11 months 26 days

STOCKHOLDERS' EQUITY (Details 4

STOCKHOLDERS' EQUITY (Details 4) - Common Stock Purchase Warrant [Member] - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Option Indexed to Issuer's Equity [Line Items]
Outstanding at beginning of period	3,548,302
Weighted average exercise price, Outstanding at beginning of period	$ 0.73
Weighted Average remaining life, Outstanding	3 years 5 months 23 days	4 years 9 months 18 days
Granted	3,497,918
Weighted average exercise price, Granted	$ 0.81
Weighted Average remaining life, Granted	4 years 3 months 7 days
Exercised	(3,951,344)
Weighted average exercise price, Exercised	$ 0.59
Cancelled/Expired	0
Weighted average exercise price, Expired	$ 0
Outstanding at end of period	3,094,876	3,548,302
Weighted average exercise price, Outstanding at ending of period	$ 1	$ 0.73

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)																	6 Months Ended		12 Months Ended
	Jun. 14, 2024	Apr. 05, 2024	Feb. 20, 2024	Feb. 15, 2024	Feb. 13, 2024	Dec. 04, 2023	Oct. 23, 2023	Sep. 28, 2023	Aug. 01, 2023	Jul. 28, 2023	Jun. 26, 2023	Apr. 27, 2023	Mar. 31, 2023	Feb. 10, 2023	Dec. 30, 2022	Jul. 14, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 20, 2023	Feb. 06, 2014
Class of Stock [Line Items]
Preferred stock shares authorized																	10,000,000	10,000,000	10,000,000	10,000,000
Preferred stock, par value																	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, shares issued																	0	0	0	0
Preferred stock, shares outstanding																	0	0	0	0
Common stock, shares authorized																	350,000,000	350,000,000	350,000,000	350,000,000
Common stock, par value																	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares issued																	155,027,245	63,698,144	155,027,245	63,698,144
Common stock, shares outstanding																	155,027,245	63,698,144	155,027,245	63,698,144
Common stock, shares issuable																	2,189,672		2,189,672
Obligation to purchase																					$ 20,000,000
Extinguishment loss																			$ (1,303,578)	$ 0
Settlement of debt																			1,183,560
Issuance of common stock shares				50,000		525,945
Issuance of common stock shares, value						$ 341,865
Exercise price											$ 0.53		$ 1.14
Issuance of common stock under private placement				344,827
Common stock par value under private placement				$ 0.0001
Proceeds of private placement offering				$ 1,000,000									$ 2,711,000						3,000,000	$ 4,011,823
Notes payable											$ 1,200,000
Shares issued of common stock, value																			489,000
Earn-out distribution																$ 2,762,500
Share price																$ 2.21
Extinguishment of contingent consideration liability																			$ 419,182
Common stock reserved for issuance																	17,414	17,414	17,414	17,414
Stock based compensation expense																			$ 4,673,129	$ 3,535,051
Unrecognized compensation cost																	$ 250,373		250,373
Stock based compensation expense																			$ 4,673,129	$ 3,535,051
Common Stock Purchase Warrants [Member]
Class of Stock [Line Items]
Common stock purchase warrants exercisable outstanding																	3,094,876		3,094,876
Total intrinsic value of options exercisable																	$ 2,309,681		$ 2,309,681
Share-Based Payment Arrangement, Tranche One [Member]
Class of Stock [Line Items]
Option granted																			0	184,800
Shares forfeited																			0	18,960
Share-Based Payment Arrangement, Tranche Two [Member]
Class of Stock [Line Items]
Option granted																			0	73,200
Shares forfeited																		0		12,640
Equity Incentive Plan 2014 [Member]
Class of Stock [Line Items]
Common stock reserved for issuance																						1,206,000
Plan Options [Member]
Class of Stock [Line Items]
Option granted																			6,665,821
Options available to be issued																			4,515,873
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Shares issued														100,000
Converted shares of common stock, shares												100,000
Converted shares of common stock, value												$ 120,000		$ 108,000
Restricted Stock Awards [Member]
Class of Stock [Line Items]
Unrecognized compensation cost																	$ 1,344,843		$ 1,344,843
Stock based compensation expense																			$ 1,415,157	$ 108,000
Number of shares grant																			1,000,000	100,000
Number of value grant																			$ 2,760,000
Stock Purchase Agreement Of Renovaro Cube [Member]
Class of Stock [Line Items]
Issuance of common stock shares					70,834,183
Issuance of common stock shares, value					$ 136,001,631
Investor [Member]
Class of Stock [Line Items]
Shares sold																			2,671,631
Paid in cash and settlement of debt																			$ 478,060	$ 478,060
Principal amount and interest accrued																			$ 3
Investor 1 [Member]
Class of Stock [Line Items]
Shares sold																				317,715
Paid in cash and settlement of debt																				$ 66,000
Principal amount and interest accrued																				$ 468,453
Renovaro Bio Pharma Inc [Member]
Class of Stock [Line Items]
Share price																$ 2.21
Dan Drit Denmark [Member]
Class of Stock [Line Items]
Common stock, shares outstanding																		167,639		167,639
Renovaro Denmark [Member]
Class of Stock [Line Items]
Common stock issued																			0	0
Employees [Member]
Class of Stock [Line Items]
Option granted																			369,500	193,000
Employees 1 [Member]
Class of Stock [Line Items]
Option granted																	65,000
Board Of Directors And Scientific Advisory Board One [Member]
Class of Stock [Line Items]
Option granted																			424,412	355,359
Board Of Directors And Scientific Advisory Board Two [Member]
Class of Stock [Line Items]
Option granted																			329,729	0
Consulting Services [Member]
Class of Stock [Line Items]
Option granted																			10,000	75,000
Renovaro Cube [Member]
Class of Stock [Line Items]
Preferred Stock, Convertible, Shares Issuable					561,010
Conversion of Stock, Shares Issued					5,610,100
Extinguishment loss																			$ 120,018
EBI And Weird Science LLC [Member] | Agreement And Plan Of Merger Agreement Axis [Member]
Class of Stock [Line Items]
Common shares contingently issuable																	0		0
Purchase Agreement [Member]
Class of Stock [Line Items]
Shares issued																					696,021
Private Placement [Member]
Class of Stock [Line Items]
Shares issued											567,588
Closed private placement units	5,315,215
Closed shares, par value	$ 0.0001
Exercise price per share	$ 1.4765
Shares sold																			2,325,869
Price per unit																	$ 1.4726		$ 1.4726
Paid in cash and settlement of debt																			$ 3,425,075
Exercise price											$ 0.53
Proceeds of private placement offering											$ 300,822
Share price											$ 0.0001
One Warrant [Member]
Class of Stock [Line Items]
Exercise price											$ 0.53		$ 1.14
Series A Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																	10,000,000		10,000,000
Preferred stock, par value																	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock designated shares																	1,000,000	1,000,000	1,000,000	1,000,000
Preferred stock, shares issued																	0	0	0	0
Preferred stock, shares outstanding																	0	0	0	0
Preferred Stock Issuances [Member]
Class of Stock [Line Items]
Common stock, par value									$ 7.13
Shares issued									280,505
Closed private placement units									280,505
aggregate proceeds									$ 2,000,000
Conversion of promissory note									$ 2,000,000
Aggregate preferred stock shares																			561,010
Aggregate common stock shares																			5,610,100
Warrants sold																	2,805,050		2,805,050
Exercise price																			$ 0.65
Common Stock Issuances [Member]
Class of Stock [Line Items]
Issuance of common stock shares		33,760						2,000,000		2,000,000
Issuance of common stock shares, value		$ 94,190		$ 100,000				$ 4,470,000		$ 4,470,000
Warrant [Member]
Class of Stock [Line Items]
Shares issued													1,189,036
Common stock purchase warrants exercisable outstanding			2,953,700
Warrants aggregate amount			1,750,000
Proceeds from common stock																$ 1,625,000
Share price																$ 2.21
Shares purchased																1,250,000
Non cash earn out distribution																$ 2,762,500
Warrant [Member] | Single Range [Member]
Class of Stock [Line Items]
Common stock purchase warrants exercisable outstanding			471,699
Exercise price			$ 0.53
Warrants aggregate amount			250,000.
Warrant [Member] | Minimum [Member]
Class of Stock [Line Items]
Exercise price			$ 0.53
Warrant [Member] | Maximum [Member]
Class of Stock [Line Items]
Exercise price			$ 0.65
Advisory Services [Member]
Class of Stock [Line Items]
Issuance of common stock shares							1,000,000
Issuance of common stock shares, value							$ 2,760,000
Common Stock [Member]
Class of Stock [Line Items]
Shares issued											4,718,532		2,378,070
Proceeds of private placement offering											$ 1,300,823
Number of share warrant purchase											2,359,266
Issuance of shares															198,439
Shares issued of common stock, value															$ 204,392
Purchase shares of common stock																1,250,000
Proceeds from common stock																$ 1,625,000
Common Stock [Member] | Lincoln Park [Member]
Class of Stock [Line Items]
Shares issued																					696,021

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Sep. 10, 2021	Aug. 25, 2021	Feb. 06, 2020	Jan. 31, 2020	Nov. 15, 2019	Jun. 30, 2024	Jun. 30, 2023
Defined Benefit Plan Disclosure [Line Items]
Up-front payment					$ 10,000,000
Payment for expenditures					$ 760,000
Initial payment	$ 600,000	$ 600,000
Remaining shares						17,414	17,414
G Tech [Member] | License Agreement [Member]
Defined Benefit Plan Disclosure [Line Items]
Payment for license			$ 1,200,000	$ 1,200,000
Royalty percentage				2%

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)							12 Months Ended
	Feb. 16, 2024	Feb. 05, 2024	Jan. 12, 2024	Jan. 11, 2024	Jan. 02, 2024	Nov. 03, 2023	Jun. 30, 2024	Jun. 30, 2023	Jun. 26, 2023	Mar. 31, 2023
Related Party Transaction [Line Items]
Warrant exercise price per share									$ 0.53	$ 1.14
Gross proceeds							$ 3,770,512	$ 0
January Note 2024 [Member]
Related Party Transaction [Line Items]
Principal amount			$ 125,000	$ 460,000
Gross proceeds			$ 125,000
Interest rate				12%
Debt maturity period			Dec. 29, 2024	Jan. 11, 2025
November 2023 Note [Member]
Related Party Transaction [Line Items]
Amortization discount							50,000
Mark Dybul [Member]
Related Party Transaction [Line Items]
Accrued balance							220,402
RS Bio [Member]
Related Party Transaction [Line Items]
Warrant exercise price	471,699
Warrant exercise price per share	$ 0.53
Proceeds from notes payables	$ 250,000
Original issue discount promissory note percentage		5%
Principal amount		$ 105,263
Gross proceeds		$ 100,000
Gross proceeds original issue discount rate		5%
Interest rate		12%
Debt maturity period		Mar. 01, 2024
Amortization discount							5,263
Interest expense							6,316
Note balance							105,263
Interest rate		12%
RS Bio [Member] | January Note 2024 [Member]
Related Party Transaction [Line Items]
Original issue discount promissory note percentage					5%
Principal amount					$ 526,315
Gross proceeds					$ 500,000
Gross proceeds original issue discount rate					5%
Debt maturity period					Mar. 01, 2024
Amortization discount							26,315
Interest expense							31,579
Note balance							$ 526,315
Interest rate					12%
RS Bio [Member] | November 2023 Note [Member]
Related Party Transaction [Line Items]
Original issue discount promissory note percentage						5%
Principal amount						$ 1,000,000
Gross proceeds						$ 950,000
Gross proceeds original issue discount rate						5%
Debt maturity period					Mar. 01, 2024	Jan. 01, 2024
Interest rate						12%
Discount accreted						$ 50,000
Interest rate						12%

ACQUISITION (Details)

ACQUISITION (Details) - GEDi Cube [Member]	Feb. 13, 2024 USD ($)
Business Acquisition [Line Items]
Common stock	$ 136,001,631
Contingent consideration	20,557,500
Total consideration transferred	$ 156,559,131

ACQUISITION (Details 1)

ACQUISITION (Details 1) - USD ($)	Jun. 30, 2024	Feb. 13, 2024	Jun. 30, 2023
Business Acquisition [Line Items]
Goodwill	$ 159,330,161		$ 11,640,000
GEDi Cube [Member]
Business Acquisition [Line Items]
Cash		$ 65,851
Prepaid & Other Assets		151,544
Fixed Assets		16,243
Operating lease ROU		624,366
Total Assets Acquired:		858,004
Accounts Payable		583,577
Accrued Expenses		722,508
Operating Lease liability		624,367
Notes Payable		1,832,460
Total Liabilities Assumed		3,762,913
Net Assets Acquired		(2,904,909)
Goodwill		159,464,040
Total Consideration		$ 156,559,131

ACQUISITION (Details 2)

ACQUISITION (Details 2) - GEDi Cube [Member]	12 Months Ended
	Jun. 30, 2024 USD ($)
Business Acquisition [Line Items]
Revenues	$ 0
Net loss	$ (1,243,144)

ACQUISITION (Details 3)

ACQUISITION (Details 3) - GEDi Cube [Member] - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Business Acquisition [Line Items]
Revenues	$ 0	$ 0
Net loss	$ (83,571,822)	$ (42,490,305)

ACQUISITION (Details Narrative)

ACQUISITION (Details Narrative) - GEDi Cube [Member] - USD ($) $ in Millions		12 Months Ended
	Feb. 13, 2024	Jun. 30, 2024
Business Acquisition [Line Items]
Fair value of consideration transferred amount	$ 156.6
Acquisition related costs		$ 1.2

SEGMENT REPORTING (Details)

SEGMENT REPORTING (Details)	12 Months Ended
	Jun. 30, 2024 USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating income loss	$ 81,639,296
Assets	163,129,450
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating income loss	80,470,579
Assets	2,998,311
NETHERLANDS
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating income loss	1,168,716
Assets	$ 160,131,139

SEGMENT REPORTING (Details 1)

SEGMENT REPORTING (Details 1) - USD ($)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Segment Reporting Information [Line Items]
General and administrative	$ 24,557,608
Research and development	2,708,829	$ 4,165,197
Intangible asset impairment	42,611,000	18,960,000
Goodwill impairment	11,640,000
Depreciation and amortization	121,859	$ 113,496
Segment operating loss	81,639,296
RENB [Member]
Segment Reporting Information [Line Items]
General and administrative	23,449,158
Research and development	2,651,971
Intangible asset impairment	42,611,000
Goodwill impairment	11,640,000
Depreciation and amortization	118,450
Segment operating loss	80,470,579
RENC [Member]
Segment Reporting Information [Line Items]
General and administrative	1,108,449
Research and development	56,858
Intangible asset impairment	0
Goodwill impairment	0
Depreciation and amortization	3,409
Segment operating loss	$ 1,168,716

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member] - USD ($)			3 Months Ended
	Aug. 23, 2024	Aug. 01, 2024	Oct. 02, 2024
Subsequent Event [Line Items]
Sale of stock issued			1,525,316
Sale of stock price per share			$ 1.4726
Sale of stock issued cash consideration			$ 2,246,181
Issuance of common stock shares		2,000,000
Common stock for consulting services value		$ 1,400,000
Restricted Stock Awards [Member]
Subsequent Event [Line Items]
Forfeited shares of common stock	833,333
Original shares of common stock	1,000,000
Option to purchase shares of common stock	978,261
Option to purchase shares of common stock par value	$ 0.69